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Herpes simplex virus 2 (HSV-2) is the primary causative agent of genital herpes, a 
disease characterized by painful recurrent anogenital lesions, higher risks for HIV and 
other STD transmissions, and potential childbirth complications. Despite the large 
medical burden of HSV-2, no vaccines are currently available. Most HSV-2 vaccine 
candidates have been subunit vaccines due to safety concerns, but live attenuated 
vaccines (LAVs) should be considered. Codon pair bias (CPB) is the phenomenon that 
specific codons pairs appear more frequently than expected. CPB deoptimization 
(CPBD) has been shown to significantly attenuate polio, influenza, and Streptococcus 
pneumoniae, indicating that CPBD is a viable attenuation method and LAV strategy. 
However, CPBD has never been used to attenuate DNA viruses, so its ability to 
attenuate these viruses remains unknown. This thesis describes the usage of CPBD to 
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Chapter 1: Introduction 
Section 1: HSV-2 Characteristics  
Viral Family. Herpesviridae is a large viral family of linear double-stranded, nuclear-
replicating DNA viruses that infect a wide variety of species that includes mollusks, 
fish, birds, and mammals (Akhtar and Shukla 2009; McAllister and Schleiss 2014). 
Herpesviridae is further divided into three subfamilies – Alphaherpesvirinae, 
Betaherpesvirinae, and Gammaherpesvirinae – all of which contain animal and human 
pathogens that cause various diseases (Akhtar and Shukla 2009; McAllister and 
Schleiss 2014). These viral subfamilies arose between 220-180 million years ago, 
allowing these viruses to carefully adapt to their specific host species and evade 
immune responses (Ellerman-Eriksen 2005; Grinde 2013).  
Multiple herpesviruses pose significant medical problems for veterinary science 
and farming such as suid herpesvirus 1 or pseudorabies virus (PRV) and equid 
herpesvirus 1 (EHV-1) (Tischer and Osterrieder 2010). In pigs, PRV causes Aujeszky’s 
disease, which is characterized by abortions, stillbirths, seizures, and fever (Pomeranz, 
Reynolds, and Hengartner 2005); the mortality rate for piglets is almost 100%, resulting 
in large financial losses for swine farmers (Pomeranz, Reynolds, and Hengartner 2005). 
EHV-1 can cause abortions in pregnant mares as well as neurological problems, which 
are costly for farmers and ranchers (Ma, Azab, and Osterrieder 2013). Live attenuated 
vaccines (LAVs) for PRV, bovine herpesvirus 1, and Marek’s disease already exist, but 
vaccines for animal herpesviruses should continue to be developed to prevent economic 





Some herpesviruses, particularly gallid, equid, and primate herpesviruses, have 
been shown or are suspected to pose a zoonotic threat (Tischer and Osterrieder 2010). 
Cercopithecine herpesvirus 1 or Herpes B virus, which naturally infects macaques and 
presents the same symptomatic and viral lifecycle profile as herpes simplex virus type 
1 (HSV-1) does in humans, has been classified as a bioterrorism agent due to its ability 
to cause severe encephalitis in infected patients (Tischer and Osterrieder 2010).    
Currently nine human herpesviruses (HHV-1, 2, 3, 4, 5, 6a, 6b, 7, and 8) have 
been discovered (Suazo et al. 2015). These herpesviruses cause a wide range of diseases 
with different symptoms, such as the alphaherpesviruses herpes simplex virus type 1 
(HSV-1) and type 2 (HSV-2), which cause oral and genital herpes, respectively (Grinde 
2013); the gammaherpesvirus Epstein-Barr virus (EBV), which causes infectious 
mononucleosis and chronic active EBV (Grinde 2013); the alphaherpesvirus varicella-
zoster virus (VZV), which causes chickenpox and shingles (Grinde 2013); and the 
betaherpesvirus cytomegalovirus (CMV), which causes birth defects including mental 
retardation and deafness (Grinde 2013). Thus, herpesviruses constitute a substantial 
disease burden that affects infants, adults, and the elderly, driving multiple vaccine 
efforts for these viruses. 
Virion Structure. Herpesviruses have a large, linear dsDNA genome ranging from 124-
230 kbp with a unique long (UL) and unique short (US) region flanked by inverted 
repeats (Akhtar and Shukla 2009; Dolan et al. 1998; McAllister and Schleiss 2014). 
The 155 kbp HSV-2 viral genome is enclosed in the nucleocapsid, which is surrounded 
by the tegument, an area between the capsid and the envelope that contains many viral 





immune responses (Figure 1) (Akhtar and Shukla 2009; Batterson and Roizman 1983; 
Ellerman-Eriksen 2005; Read and Frenkel 983; Zhou et al. 1999). The tegument is then 
surrounded by the envelope, which is studded with multiple glycoproteins that serve 
different functions (Akhtar and Shukla 2009; Ellerman-Eriksen 2005; McAllister and 
Schleiss 2014; Nicola and Strauss 2004). For example, gD mediates virion attachment 
to host cells, gB facilitates successful fusion of the viral envelope and the host cell 
membrane, and gH/gL activates gB by inducing conformational changes (Akhtar and 
Shukla 2009; Ellerman-Eriksen 2005; Nicola and Strauss 2004). These glycoproteins, 
specifically gD and gB, have been popular for use in subunit vaccines due to their 
exposure to the immune system and their essential functions to successful viral 
infection. 
Viral Lifecycle. HSV-2 has a complex lifecycle that spans across two different types of 
susceptible host cells as gD has the ability to bind two different receptors, giving HSV-
2 a dual tropism of both epithelial and neuronal cells (Figure 3). During primary 
infection, the virus lytically infects epithelial cells surrounding the genital mucosa via 
the attachment of gD to its receptor herpesvirus entry mediator (HVEM), a member of 
the tumor necrosis factor receptor family (Akhtar and Shukla 2009; Carfí et al. 2001; 
Connolly et al. 2005; Heldwein and Krummenacher 2008; Montgomery et al. 1996; 
Suazo et al. 2015). Receptor attachment prompts conformational changes to activate a 
complex of two other surface glycoproteins, gH/gL, which then induces conformational 
changes in gB to activate its fusogenic properties to successfully fuse the viral and host 
cell membranes (Akhtar and Shukla 2009; Coleman and Shukla 2013; Heldwein and 





endocytosis pathway (Akhtar and Shukla 2009; Clement et al. 2006; Coleman and 
Shukla 2013; Suazo et al. 2015).  
 Once inside the host cell, the tegument releases dozens of proteins that perform 
many different functions such as transport, immune evasion, apoptosis, and host cell 
translation inhibition (Coleman and Shukla 2013; Suazo et al. 2015). The capsid is 
transported to the nuclear membrane by the microtubule system via the tegument 
proteins VP1-2 and UL37 (Akhtar and Shukla 2009; McAllister and Schleiss 2014; 
Suazo et al. 2015). The capsid docks onto the nuclear pore complex (NPC) to inject the 
viral DNA into the nucleus so it can be transcribed by host cell RNA polymerase II 
(McAllister and Schleiss 2014; Suazo et al. 2015). Viral gene transcription is sequential 
in which the protein products of earlier transcribed genes initiates transcription of later 
genes (Suazo et al. 2015). Immediate early (IE) or alpha genes are transcribed first as 
they are important for immune evasion and decreasing host cell translation (Ellerman-
Eriksen 2005; McAllister and Schleiss 2014; Suazo et al. 2015). Early (E) or beta genes 
are transcribed second as they are necessary for viral DNA replication (Ellerman-
Eriksen 2005; McAllister and Schleiss 2014; Suazo et al. 2015). Early late (EL) or 
gamma-1 as well as Late (L) or gamma-2 genes are transcribed last as they encode 
virion capsid, tegument, and surface structural components (Ellerman-Eriksen 2005; 
McAllister and Schleiss 2014; Suazo et al. 2015).  
 Once capsid proteins are made, they migrate into the nucleus to enclose viral 
genomes and acquire various tegument proteins (Suazo et al. 2015). Capsids are 
enveloped by the nuclear inner membrane as they exit the nucleus, but almost 





al. 2015). Therefore, the teguments are re-exposed upon the entry of the capsids into 
the cytoplasm to allow additional tegument protein acquisition before re-envelopment 
at the trans-Golgi network (Suazo et al. 2015). The mature virions are then released 
from the cell via vesicles where they can continue to lytically infect epithelial cells or 
infect neuronal cells to establish latency (Suazo et al. 2015).          
The virus travels to neuronal cells innervating the area and infects them via 
nectin-1, a member of the immunoglobulin (Ig) superfamily (Connolly et al. 2005; 
Lopez et al. 2001; Spear, Eisenberg, and Cohen 2000). Once in the neurons, the virus 
travels up the axons to establish a state called latency in the nuclei of the cells of the 
dorsal root ganglia (DRG) (Chentoufi and BenMohamed 2012; Coleman and Shukla 
2013; Grinde 2013; McAllister and Schleiss 2014). Latency is characterized by viral 
replication suppression mediated by low level transcription of pro-latency genes such 
as the latency-associated transcript (LAT) (Chentoufi and BenMohamed 2012; Egan et 
al. 2013). Unfortunately, not much is known about how the virus establishes or 
maintains latency or what factors control reactivation (Egan et al. 2013). However, it 
is assumed that both viral and host characteristics and interactions play a role in 
determining the duration of latency as well as the frequency of reactivation (Egan et al. 
2013). Latency is also thought to be evolutionarily advantageous as it permanently 
shields the virus from the host immune system between outbreaks (Chentoufi and 
BenMohamed 2012; Egan et al. 2013; Ellerman-Eriksen 2005; Grinde 2013). Latency 






Periodically, triggers such as physical or chemical stress, immunosuppression, 
or UV light will reactivate the virus from its latent state in the neurons to initiate 
recurrent outbreaks of lesions (Chentoufi and BenMohamed 2012; Chentoufi et al. 
2012; Coleman and Shukla 2013; McAllister and Schleiss 2014). The virus is also 
capable of spontaneous reactivation independent of triggers (Chentoufi and 
BenMohamed 2012). Genome replication and transcription of pro-lytic genes, viral 
protein production, and virion assembly occur in the cytoplasm of infected neuronal 
cells (McAllister and Schleiss 2014). Virions travel back down the axons into the 
surrounding epithelia to initiate viral replication (Coleman and Shukla 2013; 
McAllister and Schleiss 2014). Symptomatic outbreaks may occur from 4-15 times 
annually with lesions present for 3-12 days (Wald et al. 1997); HSV-2 can be isolated 
from these lesions 1-4 days after onset, giving a relatively wide window for 
transmission to sexual partners (Wald et al. 1997). Reactivation is a risky process for 
the virus considering lytic replication will induce a host immune response, but it does 
allow the virus opportunities to be transmitted to new hosts.  
The HSV-2 lifecycle is not only confined to latency inspired by symptomatic 
outbreaks of lesions. Subclinical shedding is defined by frequent episodes of viable 
HSV-2 virions being “shed” or released into the genital mucosa without symptoms 
(Coleman and Shukla 2013; Egan et al. 2013; Mertz et al. 1992; Wald et al. 1997; Wald 
et al. 1995). Subclinical shedding significantly contributes to continued HSV-2 
transmission because no identifiable familiar symptoms of a herpetic outbreak are 
present, which might convince individuals that they are HSV-2 negative and/or to 





2013; Egan et al. 2013; Johnston, Koelle, and Wald 2011; Wald et al. 2000). 
Mathematical models have shown subclinical shedding episodes are frequent and 
overlapping with widespread bilateral shedding throughout the genital mucosa, but also 
short (Crespi et al. 2007; Mark et al. 2008; Schiffer et al. 2009; Tata et al. 2010); 
reactivations last a median of about 13 hours as the constant low leak of virus from the 
DRG is rapidly cleared by the host immune system (Crespi et al. 2007; Mark et al. 
2008; Schiffer et al. 2009; Tata et al. 2010). Widespread bilateral shedding throughout 
the genital mucosa suggests that distinct reactivations from different ganglia are 
occurring simultaneously, but factors such as the titer of virus and persistence of HSV-
2-specific CD8+ T cells in the mucosa determine which reactivations are cleared and 
which progress to lesions (Crespi et al. 2007; Tata et al. 2010; Zhu et al. 2007).  
Wald and colleagues showed that subclinical viral shedding is quite common in 
that the median positive HSV-2 shedding day percentage was 24% with a range as wide 
as 0% to 75% (Wald et al. 1997); that is, the average HSV-2-positive woman sheds 
HSV-2 24 days out of 100 days, but some women may not shed at all and other may 
shed more than 75 days out of 100 days (Wald et al. 1997).  The titers of HSV-2 shed 
also widely varied among women, with higher average titers seen when lesions were 
present as would be expected (Wald et al. 1997). On HSV-2-culture-positive days, the 
presence of lesions had no effect on the amount of HSV-2 DNA found in the mucosa, 
indicating that lesion-causing levels of HSV-2 DNA can be shed without any symptoms 
which would increase transmission risk on those days (Wald et al. 1997).  Another 





showing that asymptomatic individuals are silent carriers that can still transmit the virus 
to individuals who may develop symptoms (Tronstein et al. 2011).        
Section 2: HSV-2 Disease 
Genital Herpes. Herpes simplex virus type 2 (HSV-2) is the primary causative agent of 
genital herpes (Wald et al. 1997). As described previously, HSV-2 is spread through 
intimate contact initially by lytically infecting epithelial cells in the genital region and 
then establishing latency in the DRG, thereby establishing a lifelong infection in the 
host (Akhtar and Shukla 2009; Suazo et al. 2015). The virus then periodically 
reactivates in the neurons, traveling down neuronal axons into the surrounding 
epithelial tissue to cause ulcers in symptomatic individuals (Akhtar and Shukla 2009; 
Suazo et al. 2015). These ulcers may present on the anal, penile, and labial tissues in 
different numbers and sizes (Wald et al. 1997). The severity, number, and duration of 
subsequent outbreaks in symptomatic individuals also vary, which can provide 
prognostic difficulties (Wald et al. 1997). 
  Unfortunately, multiple societal and viral characteristics contribute to the 
continued transmission of HSV-2. The societal stigma against herpes and the 
accompanying shame and distress prevents many symptomatic individuals from 
seeking treatment as well as informing their sexual partners (Dropulic and Cohen 2012; 
Green and Kocsis 1997). Both symptomatic and asymptomatic infected individuals 
frequently have subclinical shedding of the virus, meaning that these individuals can 
pass on their infection despite showing no symptoms (Johnston, Koelle, and Wald 
2011; McAllister and Schleiss 2014; Mertz et al. 1992; Wald et al. 1997). Over 80% of 





(Johnston, Koelle, and Wald 2011; McAllister and Schleiss 2014; Wald et al. 2000; Xu 
et al. 2002). Lack of symptoms in infected individuals allows the virus to potentially 
infect their sexual partners, contributing to the staggering 23 million new infections 
every year (Johnston, Koelle, and Wald 2011; McAllister and Schleiss 2014).  
HSV-2 genital herpes affects about 536 million people worldwide, though cases 
of HSV-1 genital herpes are on the rise due to increased transmission from unprotected 
oral sex (Hofstetter, Rosenthal, and Stanberry 2014; Johnston, Koelle, and Wald 2011; 
Looker et al. 2008; Ryder et al. 2009). In the United States alone, about 20% of women 
and 40% of non-Hispanic blacks are HSV-2 seropositive, which underscores the high 
prevalence of HSV-2 infection in different subpopulations (Awasthi and Friedman 
2014; Chentoufi and BenMohamed 2011). Many of these subpopulations, especially 
women, are also at higher risk for contracting HIV or other STIs such as human 
papillomavirus, which is associated with cervical cancer and genital warts, due to a 
number of factors (Abu-Raddad et al. 2008; Chentoufi and BenMohamed 2011; 
Milligan, Bernstein, and Bourne 1998). Such factors include but are not limited to 
location (Rajagopal et al. 2014; Kagee et al. 2011); socioeconomic status (Kagee et al. 
2011); no or little access to healthcare and health education (Kagee et al. 2011; 
Kalichman and Simbayi 2004); inability to pay for such healthcare or transport to 
clinics due to being poor, uninsured, underinsured, or not insured at all (Kagee et al. 
2011; Kagee, Le Roux, and Dick 2007); cultural or religious beliefs (Kagee et al. 2011); 
and gender roles, sexual expectations of women, relationship dynamics and power 
inequality, and domestic violence (Jewkes and Morrell 2010). Sub-Saharan Africa has 





regions, especially in women and subpopulations at higher sexual risk – which 
continues to perpetuate the HIV/AIDS epidemic there (Johnston, Koelle, and Wald 
2011; Paz-Bailey et al. 2007; Rajagopal et al. 2014; Smith and Robinson 2002). Despite 
HSV-2 itself not usually being life-threatening, being HSV-2 seropositive puts 
individuals – especially immunocompromised individuals such as newborns, 
HIV/AIDS patients, and patients on immunosuppressive drugs – at higher risk for both 
severe HSV disease and other infections that can be fatal (Akhtar and Shukla 2009; 
Chentoufi and BenMohamed 2011; Egan et al. 2013; Herget et al. 2005).  
HSV-2/HIV Co-Infection. HSV-2 co-infection is highly correlated with human 
immunodeficiency virus (HIV) infections in both developing and developed countries 
(Awasthi and Friedman 2014; Rajagopal et al. 2014). Sub-Saharan Africa bears a 
disproportionate burden of HSV-HIV co-infection with up to 90% of HIV-positive 
people also testing HSV-2-positive (Abu-Raddad et al. 2008; Rajagopal et al. 2014).     
HSV-2 lesion disruption of the genital mucosa and the frequency of subclinical 
shedding recruit HIV-susceptible immune cells such as CD4+ T cells to these areas and 
induce long-term persistence in the mucosa (Corey et al. 2004; Freeman et al. 2006; 
Johnston, Koelle, and Wald 2011; Koelle et al. 1998; Zhu et al. 2009). This long-term 
persistence of CD4+ T cells enables HIV to more successfully establish infection in 
these individuals, resulting in HSV-2 seropositive people having a 2-4-fold increase in 
HIV acquisition risk (Corey et al. 2004; Freeman et al. 2006; Johnston, Koelle, and 
Wald 2011; Zhu et al. 2009).  
Conversely, HIV/AIDS increases the severity and duration of HSV-2 lesions, 





al. 2004; Freeman et al. 2006). Due to HIV/AIDS patients’ decreased immunity and 
HSV-2’s neurotropism, HSV-2 can infect their spinal cords to cause visceral disease 
(Britton et al. 1985). HSV-2/HIV-double-seropositive people also have a 2-5-fold 
increase in transmitting HIV to sexual partners compared to HIV-positive, HSV-2-
negative individuals (Abu-Raddad et al. 2008; Gray et al. 2001; Latif et al. 1989). This 
increase in risk may be due to the fact that HSV-2 increases HIV transcription in vitro, 
leading to high levels of HIV RNA in genital lesions and plasma (Albrecht et al. 1989; 
Golden et al. 1992; Mole et al. 1997; Schacker et al. 1998; Schacker et al. 2002). HIV 
also increases HSV-2 mucosal shedding, thus increasing the transmission risk of HSV-
2 to sexual partners (Augenbraun et al. 1995; Mbopi et al. 1999; Mostad et al. 2000).  
Neonatal Herpes. Babies born to mothers with primary HSV-2 infection not controlled 
by antiviral therapy can develop disseminated neonatal herpes, which has a mortality 
rate as high as 85% if not treated (Gardella and Brown 2011; Kimberlin 2004; Whitley 
et al. 1980). Neonatal herpes is seen in approximately 1 out of 3200 live births, 
averaging about 1500 cases per year in the United States (Gardella and Brown 2011; 
Kimberlin 2004). The neonate can contract HSV-2 in three ways: in utero, which 
occurs about 5% of cases; peripartum, where the neonate contracts HSV-2 by its 
contact with herpetic lesions as it passes through the birth canal and vagina, which 
occurs in 85% of cases; and postnatal, which occurs in 10% of cases (Gardella and 
Brown 2011; Kimberlin 2004; Whitley et al. 1980). Disseminated HSV-2 infection 
usually is seen in 33-50% of all babies born with neonatal herpes (Gardella and Brown 
2011; Kimberlin 2004); disseminated HSV-2 is characterized by encephalitis and 





(Gardella and Brown 2011; Kimberlin 2004). One third of babies with HSV-2 infection 
develop CNS disease, which presents with seizures, tremors, irritability, and 
temperature instability, with death onset being due to extensive brain damage (Gardella 
and Brown 2011; Kimberlin 2004).  
Section 3: HSV-2 Immunology  
A discussion of immunology is necessary for any vaccine development field 
because a vaccine candidate’s success is almost completely based on its ability to 
induce an immune response that satisfies a certain endpoint such as preventing 
infection or disease. Gaps in knowledge about what immune responses must be elicited 
to confer immunity or eliminate disease symptoms obstructs successful vaccine 
creation, allowing continued transmission of the agent as well as maintaining or 
increasing its disease burden.  
Innate Immunity. The innate immunity system is the first arm of the immune system 
engaged in response to a pathogen invasion. This first innate immune system response 
is required for the later engagement of the adaptive immune system if the innate 
immune system cannot eliminate the pathogen on its own (Iwasaki and Medzhitov 
2015). This arm of the immune system responds very rapidly to a pathogen, but this 
response has relatively low pathogen specificity and stores no memory of any 
encountered pathogens (Iwasaki and Medzhitov 2015); therefore, subsequent 
reinfections caused by the same pathogen results in the same innate immune response 
without any maturation that might improve pathogen neutralization and clearance 





Innate immune responses may be broken in the two major defenses of 
anatomical barriers such as skin and cytokine-cell interactions initiated by certain 
receptors that activate the many subpopulations of innate immune cells. Anatomical 
barriers such as skin obviously protect organs and blood from pathogens by providing 
a physical shield to prevent contact between them (Boyton and Openshaw 2002; 
Oranges, Dini, and Romanelli 2015; Ribet and Cossart 2015; Shin and Iwasaki 2013). 
Openings into the body are also usually protected by various secretions such as oral 
and vaginal mucus, ear wax, and saliva that can trap or degrade pathogens to prevent 
viable cells or virus from proceeding further into the body of the host (Boyton and 
Openshaw 2002; Ribet and Cossart 2015). However, skin cells themselves are hosts to 
a number of pathogens including HSV-2, so skin cannot provide a completely 
impenetrable barrier to all pathogens (Bonazzi and Cossart 2011). Also, pathogens can 
still bypass barriers by entering wounds or normal openings such as the mouth, nipples, 
tear ducts, nose, and ears (Boyton and Openshaw 2002; Oranges, Dini, and Romanelli 
2015; Ribet and Cossart 2015). Some pathogens can evade or downregulate mucosal 
defenses in the nose, mouth, ears, vagina, and urethra (Boyton and Openshaw 2002; 
Ribet and Cossart 2015).  
When physical barriers are breached, the cells of the innate immune system are 
engaged via cytokine production caused by pathogen material binding to various 
extracellular and intracellular receptors (Iwasaki and Medzhitov 2015). These 
extracellular and intracellular pattern recognition receptors (PRRs) recognize 
pathogen-associated molecular patterns (PAMPs), various pathogen-only essential 





Gram-negative bacteria, triacyl and diacyl lipopeptides for mycobacteria, zymosan for 
fungi and yeast, and dsRNA and DNA:RNA hybrids for viruses (Iwasaki and 
Medzhitov 2015; Kawai and Akira 2010; Wu and Chen 2014). PPRs can be both 
displayed on the host cell membrane to bind to extracellular PAMPs and on membranes 
on organelles to bind to intracellular PAMPs (Iwasaki and Medzhitov 2015; Kawai and 
Akira 2010). Considering PAMPs are exclusive to pathogens, there is little if any 
possibility for misidentification of host or self proteins as non-self PAMPs unlike in 
adaptive immunity (Iwasaki and Medzhitov 2015; Kawai and Akira 2010).   
Once PRRs are activated, they stimulate cytokine production of interferons 
(IFNs), tumor necrosis factors (TNFs), interleukins (ILs), and colony-stimulating 
factors (CSFs) (Iwasaki and Medzhitov 2015; Kawai and Akira 2006; Uyangaa, Patil, 
and Eo 2014). These many cytokines then cause an array of downstream effects such 
as immune cell maturation, or stimulation of immune cells into an more active state 
which may include heightened cytokine production, phagocytic activity, or activation 
of other immune cells; differences in secretion levels of hormones or cytokines to 
activate or deactivate immune cells; differences in surface membrane receptor 
composition and number to increase or decrease ability to interact with other immune 
or infected host cells; and heightened ability for migration out of blood vessels to 
wound sites (Brinkman et al. 2004; Iwasaki and Medzhitov 2015; Hermesh et al. 2010; 
Kawai and Akira 2006; Thomas; Uyangaa, Patil, and Eo 2014). Some of these 
cytokines are responsible for activating professional antigen-presenting cells (APCs), 





antibody-generating molecules, to T cells (Iwasaki and Medzhitov 2015; Uyangaa, 
Patil, and Eo 2014).  
There are both membrane-bound and cytosolic PRRs that recognize PAMPs 
and activate signal cascades to create anti-pathogen cell states and alert other 
components of the immune system. Toll-like receptors (TLRs), one type of membrane-
bound PRR expressed on most phagocytic innate immune cells, are particularly 
important to innate immune system activation as they can sense a wide variety of 
pathogens and activate multiple innate immune defenses (Iwasaki and Medzhitov 2015; 
Kawai and Akira 2006; Kawai and Akira 2010; Uyangaa, Patil, and Eo 2014). Once 
TLRs bind to their pathogen ligand, they initiate signal cascades that activate the NFκB 
and MAPK pathways (Uyangaa, Patil, and Eo 2014). NFκB is a widely acting 
transcription factor that helps initiates transcription for many immune response genes 
such as iNOS, TNFα, and IL-12 (Iwasaki and Medzhitov 2015; Kawai and Akira 2010). 
TLRs also activate interferon (IFN), which induces a myriad of immune responses 
aimed at reducing viral replication and shedding (Suazo et al. 2015). Cytosolic PRRs 
include Nod-like receptors (NLRs) and RIG-I like receptors (RLRs), which also 
activate NFκB as well as caspase 1 and 9, which leads to production and secretion of 
the inflammatory cytokine IL-1 and apoptosis, respectively (Iwasaki and Medzhitov 
2015; Wu and Chen 2014).  
Many subpopulations of white blood cells (WBCs) with complex and 
sometimes overlapping jobs participate in the innate immune system (Uyangaa, Patil, 
and Eo 2014). Granulocytes and monocytes are two preceding cell types that can 





differentiate into basophils, eosinophils, and neutrophils while monocytes differentiate 
into macrophages (MΦ) and dendritic cells (DC) (Egan et al. 2013). Neutrophils and 
MΦs engulf pathogens via phagocytosis and destroy them in the resulting vesicles with 
different enzymes (Ellerman-Eriksen 2005; Egan et al. 2013). Basophils, eosinophils, 
and mast cells target parasites and are responsible for allergic reactions by releasing 
histamine (Davoine and Lacy 2014). Natural killer (NK) cells kills infected host cells 
by releasing granules to form holes in the infected cells’ membranes (Ellerman-Eriksen 
2005; Egan et al. 2013; Chan et al. 2011; Uyangaa, Patil, and Eo 2014). DCs are 
professional APCs, meaning they process pathogen peptides into recognizable 
fragments for the adaptive immune system via major histocompatibility complexes 
(MHC), which will be elaborated on later (Egan et al. 2013; Uyangaa, Patil, and Eo 
2014).   
HSV-2 Innate Immunity. Little is known about the innate immune response 
against HSV-2 besides that a lack of such a response, usually immunocompromise due 
to mutations in genes encoding certain proteins such as STAT1 or TRAF3 or to NK 
cell deficiencies, can lead to severe HSV-2 infections and encephalitis (Dropulic and 
Cohen 2011; Dropulic and Cohen 2012; Sancho-Shimizu et al. 2011).  
Interferon responses are particularly important for controlling HSV-2 infection. 
Activation of TLR3 and TLR9 is important for inducing interferon in response to HSV-
2 infection (McAllister and Schleiss 2014). Interferon has multiple downstream effects 
such as anti-viral state induction in cells, DC maturation which is important for 
activating CD8+ T cells, NK maturation and recruitment, and CD8+ T cell recruitment 





therefore, stimulating interferon production seems to be instrumental in controlling 
HSV-2 infection (McAllister and Schleiss 2014; Uyangaa, Patil, and Eo 2014). IFNα, 
IFNβ, and IFNγ have been implicated in inhibiting HSV-1 replication, which strongly 
suggests these IFNs would inhibit HSV-2 replication as well due to these viruses’ 
similarity (Leventon-Kriss et al. 1987; Sainz and Halford 2002). Sainz and Halford 
showed that pre-treatment with IFNα/β with IFNγ inhibited plaque formation in Veros 
and IFNβ/γ treatment reduced ocular lesions and latency in the trigeminal ganglia (TG) 
(Sainz and Halford 2002). This logic is further supported by reduction of lesions in 
HSV-2 seropositive individuals who apply topical IFNα to affected areas (Shupack 
1992).     
Because the innate immune system has no memory of pathogen encounters, 
activation of this system by a HSV-2 vaccine might be considered somewhat less 
important than its effect on the adaptive immune system considering that humans are 
challenged by multiple exposures of HSV-2 during their lifetimes. However, this logic 
would be detrimental to HSV-2 vaccine development since the innate immune response 
is required for adaptive immunity, a HSV-2 vaccine candidate should be evaluated on 
its ability to elicit a strong innate immune response such as interferon production to 
mature professional APCs such as DCs (McAllister and Schleiss 2014). Producing 
many professional APCs that are presenting various epitopes from different viral 
proteins would ensure a robust activation of T cells, which then would lead to a robust 
activation of B cells that would recognize more epitopes (McAllister and Schleiss 
2014). Therefore, adjuvants in particular should be evaluated on their ability to 





study by Khodai and colleagues showed that including the TLR9 agonist cPG 
significantly increased innate immune responses compared to the TLR4 agonist MPL, 
choosing adjuvants that stimulate TLR3 and TLR9 may produce more effective subunit 
vaccines (Khodai et al. 2011).  
Adaptive Immunity. Adaptive immunity is the second arm engaged in response to a 
pathogen invasion. Its two subarms, humoral immunity mediated by antibodies and 
cell-mediated immunity mediated by T cells, illustrate the many differences between 
adaptive and innate immunity’s ways of controlling infection (Uyangaa, Patil, and Eo 
2014). The adaptive arm cannot be engaged without the innate immune system, so it 
cannot react as quickly to an infection as the innate immune response (Uyangaa, Patil, 
and Eo 2014). However, it can adapt, hence its name, to the pathogen encountered, 
tailoring its humoral and cellular responses to specificities in pathogen epitopes and 
lifecycles (Flajnik and Kasahara 2010). These specialized responses are remembered 
by the adaptive immune system so when subsequent infections occur, these responses 
can further specialize to speed pathogen clearance and minimize or eliminate symptom 
duration (Flajnik and Kasahara 2010; Neuberger et al. 2000). The memory B and T 
cells of the adaptive immune response, which will be elaborated on later, are more 
rapidly activated as each subsequent infection occurs (Flajnik and Kasahara 2010; 
Neuberger et al. 2000). This phenomenon is called an anamnestic response since the 
adaptive immune system is engaged earlier and produces a more robust response during 






 Humoral Immunity. The humoral subarm is controlled by B cells, whose main 
job is to produce antibodies which are incredibly important for controlling infection 
(Irani et al. 2015). Antibodies can neutralize pathogens by binding to them to prevent 
them from infecting host cells by occluding viral attachment proteins (Irani et al. 2015). 
Antibodies can opsonize pathogens by binding to them, thus making these pathogens 
more visible to innate phagocytic immune cells like neutrophils and MΦ (Irani et al. 
2015). Antibodies are also important for activating the complement pathway (Sörman 
et al. 2014; Suazo et al. 2015). Antibodies are also important for antibody-dependent 
cellular cytotoxicity (ADCC) by binding to pathogens and NK cells (Lubinksi et al. 
2011). Due to these three major jobs, a vaccine candidate’s ability to elicit antibodies 
is intimately tied to its success as a viable vaccine.  
Antibodies consist two light and two heavy chains which form a classic Y-shape 
(Flajnik and Kasahara 2010; Litman et al. 1993; Liu and May 2012). The composition 
of these light and heavy chains depends on VDJ recombination in immunoglobulin (Ig) 
genes in immature B cells in the bone marrow before they have encountered antigen 
(Borghesi and Milcarek 2006; Flajnik and Kasahara 2010; Litman et al. 1993; Lou, 
Casali, and Xu 2015; Neuberger et al. 2000; Papavasiliou and Schatz 2002); VDJ 
recombination along with junctional diversity yields a myriad of different antibodies 
theoretically capable of binding virtually any antigen (Borghesi and Milcarek 2006; 
Litman et al. 1993; Neuberger et al. 2000; Papavasiliou and Schatz 2002). The tips of 
the arms of the Y (Fab) are two variable regions that undergo somatic hypermutation to 
better bind antigen while the tail of the Y (Fc) is a constant region that binds to immune 





Schatz 2002; Sörman et al. 2014). Somatic hypermutation, or increased mutation rate 
in these antigen-binding regions in response to an antigen encounter, increases 
subsequent antibodies’ affinity for these antigen (Neuberger et al. 2000; Papavasiliou 
and Schatz 2002). This process of affinity maturation occurs during each subsequent 
infection to generate antibodies with higher affinity for their antigen, which can prevent 
illness from recurring during these subsequent infections (LeBien and Tedder 2008; 
Neuberger et al. 2000). Antibodies can be made in five different isotypes – IgM, IgG, 
IgA, IgE, and IgD – via class switching of the constant heavy chain so they can interact 
with different types of immune cells and activate different cytokine pathways (Flajnik 
and Kasahara 2010; Irani et al. 2015; Lou, Casali, and Xu 2015; Neuberger et al. 2000).   
During primary infection, B cells with antibodies that successfully bind antigen 
are stimulated by both antigen encounter and help from T cells to proliferate into 
plasma B cells or memory B cells (Bortnick et al. 2012; Kurosaki, Kometani, and Ise 
2015; Neuberger et al. 2000; Shlomchik and Weisel 2012). The pathways and signals 
that determine B cell differentiation into plasma or memory B cells are mostly 
unknown, although new research has pinpointed the transcription factors XBP1, IRF4, 
and Blimp1 as important (Lou, Casali, and Xu 2015; Nutt et al. 2011; Piccaluga et al. 
2015).  
Plasma B cells make large quantities of antibodies whose antigen affinity 
increases during the course of infection as somatic hypermutation occurs (LeBien and 
Tedder 2008; Lou, Casali, and Xu 2015; Nutt et al. 2015). Once the infection is cleared, 
most plasma B cells die by apoptosis and the large amounts of antibodies secreted by 





B cells still reside in the bone marrow where they also produce antibodies, leading to 
an increase in baseline antibody titers which contributes to the faster anamnestic 
response during later infections (Bortnick et al. 2012; Neuberger et al. 2000; Nutt et al. 
2015; Shlomchik and Weisel 2012).  
Memory B cells already have class-switched, affinity-matured antibodies from 
their encounter with antigen during the primary response, but do not replicate or secrete 
antibody until they re-encounter their antigen (Kurosaki, Kometani, and Ise 2015; 
Neuberger et al. 2000; Shlomchik and Weisel 2012). Memory B cells wait in the lymph 
nodes and spleen to be rapidly activated and differentiate again into plasma and 
memory B cells upon subsequent antigen encounters (Kurosaki, Kometani, and Ise 
2015; Shlomchik and Weisel 2012). Plasma and memory B cells created by secondary 
infections undergo further class switching as well as further somatic hypermaturation, 
which leads to even greater affinity maturation of their antibodies (Kurosaki, Kometani, 
and Ise 2015; Nutt et al. 2015; Shlomchik and Weisel 2012). Recreation of memory B 
cells during each infection ensures pathogen memory continues to be maintained 
(Kurosaki, Kometani, and Ise 2015; Shlomchik and Weisel 2012). Obviously, a HSV-
2 vaccine that induces long-lasting immune memory by creating a large pool of 
memory B cells with highly affinity-matured antibodies would be ideal considering 
that humans are exposed to HSV-2 throughout their lifetimes.      
Cell-Mediated Immunity. The other subarm of adaptive immunity, cellular 
immunity, is controlled by T cells, which perform a variety of roles such as activating 
B cells and killing infected host cells. The main two subclasses of T cells are helper T 





and CD8+ T cells (O’Shea and Paul 2010; Zhang and Lakkis 2015; Wherry and Ahmed 
2004). Helper T cells “help” other immune cells become activated via cytokine 
secretion and receptor-ligand binding while cytotoxic T cells directly kill infected host 
cells (O’Shea and Paul 2010; Wherry and Ahmed 2004).  
Unlike B cells whose receptors can recognize virtually any epitope, T cells can 
only recognize small linear peptides that are presented on major histocompatibility 
complexes (MHCs) (Blum, Wearsch, and Cresswell 2013; Flajnik and Kasahara 2010). 
MHC Class I are displayed on almost every host cell, which is recognized by CD8+ T 
cells (Blum, Wearsch, and Cresswell 2013); MHC Class II are displayed on 
professional APCs, which is recognized by CD4+ T cells (Blum, Wearsch, and 
Cresswell 2013). Once the respective T cell receptors have bound to their MHCs, co-
stimulation by CD28 or other molecules is required to fully activate the T cells (Chen 
and Flies 2013). Once CD4+ T cells are activated, they can bind to B cells that have 
encountered the same antigen via CD40-CD40L binding (Lou, Casali, and Xu 2015; 
O’Shea and Paul 2010). CD4+ T cells then secrete various cytokines to activate B cells 
and promote their proliferation (Lou, Casali, and Xu 2015; O’Shea and Paul 2010). 
Naïve CD8+ T cells have strict activation requirements as they can kill other cells by 
lytic granules, which include presentation of antigen via MHC Class II from APCs and 
CD4+ T cell help by cytokine secretion (Gutcher and Belcher 2007; Wherry and 
Ahmed 2004).    
Both CD4+ and CD8+ T cells can differentiate into both central memory (TCM) 
and effector memory (TEM) T cells (Shin and Iwasaki 2013; Willinger et al. 2005; 





periphery of the body via the bloodstream (Shin and Iwasaki 2013; Wherry and Ahmed 
2004; Zhang and Lakkis 2015). Both types of memory T cells are rapidly activated 
when they reencounter their antigen, which causes a faster immune response to and 
clearance of the pathogen (Shin and Iwasaki 2013; Wherry and Ahmed 2004; Zhang 
and Lakkis 2015). 
HSV-2 Adaptive Immunity. Not much is known about the adaptive immune 
response to HSV-2, though it is thought that antibodies are important for preventing 
infection and cellular responses are important for preventing disease. However, it is 
clear that HSV-2 IgG placental transfer is particularly important in reducing neonatal 
herpes risk during perinatal transmission (Brown et al. 2003; McAllister and Schleiss 
2014; Prober et al. 1987).  
Cell-mediated immunity, especially tissue resident T cells, is crucial in 
controlling infection as seen from the heightened risk of severe HSV infection when a 
host has a suppressed immune system due to medical treatment or HIV infection 
(McAllister and Schleiss 2014; Posavad et al. 1997; Zuckerman and Limaye 2013; Zhu 
et al. 2007; Zhu et al. 2009). Both CD4+ and CD8+ T cells play important roles during 
HSV-2 infection (Zhu et al. 2007; Zhu et al. 2009). Recruitment of CD8+ T cells to 
lesions is important for viral and infected host cell clearance (Koelle et al. 1998; Zhu 
et al. 2007); viral clearance from lesions is correlated to a rapid infiltration of HSV-2-
specific CD8+ T cells (Koelle et al. 1998; Zhu et al. 2007). Also, an inverse correlation 
between lesion severity and CD8+ T cell numbers shows that more CD8+ T cells lessen 
the severity of viral reactivation, probably due to rapid clearance of infected host cells 





controlling infection, but recruitment of these cells to genital lesions increases the risk 
of HIV transmission (Zhu et al. 2009).  
Section 4: HSV-2 Vaccine History 
Current Problems for HSV-2 Vaccine Development. Despite interest in developing both 
prophylactic and therapeutic HSV-2 vaccines as well as expensive clinical trials for 
various subunit vaccine candidates, unfortunately no HSV-2 vaccine has been licensed 
despite initial promise in animal models. Two major obstacles – unknown correlates of 
protection (CoP) and lack of non-human primate (NHP) animal models – contribute to 
the continuing failure in developing an effective human HSV-2 vaccine.  
Correlates of Protection. Unknown correlates of protection pose a significant 
challenge to any vaccine’s development. CoP describe the immune response necessary 
to induce or confer a particular immunological phenotype or endpoint (Plotkin and 
Gilbert 2012). Such endpoints are sterilizing immunity, or the ability to completely 
protect from infection and thus the gold standard for any prophylactic vaccine; disease 
immunity, or the ability to protect from symptomatic disease despite not protecting 
from infection and thus the gold standard for therapeutic vaccines; or disease reduction, 
or the ability to at least reduce the recurrence and duration of symptoms (Plotkin and 
Gilbert 2012). CoP may be further divided into mechanistic CoP (mCoP) and 
nonmechanistic CoP (nCoP) to further define how they contribute to immunity (Plotkin 
and Gilbert 2012). As defined by Plotkin and Gilbert, mCoPs are the direct immune 
responses that are responsible for conferring immunity while nCoPs are immune 
responses that highly correlate with protection, but do not provide the protection 





induction, but cellular immune responses or a combination of the two may be required 
to protect individuals for certain pathogens (Plotkin 2008).  
Establishing a mCoP for a vaccine is therefore more desirable, but establishing 
nCoPs may be easier due to available analytical assays, immune cells, and tissues 
(Plotkin and Gilbert 2012). Thus nCoPs can be more useful than mCoPs in measuring 
immunity (Plotkin and Gilbert 2012). For example, the CoP of the zoster vaccine are 
both antibodies and cellular responses as they both correlate with protection from 
shingles (Plotkin and Gilbert 2012). However, cellular responses were statistically 
stronger in their correlation, making them a mCoP and antibodies a nCoP (Plotkin and 
Gilbert 2012). Considering that measuring antibodies is easier and more 
straightforward than quantifying cellular responses, the nCoP is actually more useful 
to measure immunity in this case (Plotkin and Gilbert 2012). Knowing both mCoPs 
and nCoPs for pathogens would be advantageous for vaccine development as scientists 
would know what type and magnitude of an immune response – such as a specific titer 
of antibodies to a specific epitope – must be elicited for specific endpoints like 
sterilizing immunity or disease protection (Plotkin 2008; Plotkin and Gilbert 2012).  
Defining CoPs for vaccines is a complicated process considering how many 
variables exist in differences in individual immune systems, vaccine schedules and 
administrations, and exposure times. Each variable will be discussed in detail below. 
CoP Variables Based on Immune Responses. CoPs for infection may be 
different from CoPs from disease protection as is for the smallpox vaccine, so the 
desired endpoints of a vaccine must be assessed according to the proper CoPs (Plotkin 





be evaluated on its ability to evoke antibodies (Plotkin 2008). To make a therapeutic 
smallpox vaccine, a vaccine candidate must be instead evaluated on its ability to induce 
both antibody production and CD4+ and CD8+ T cell responses (Plotkin 2008). Also, 
vaccination may achieve one or more CoP, but not necessarily the CoP wanted. For 
example, the measles vaccine does induce protective antibody titers, but the amount 
produced determines whether the CoP of sterilizing immunity or disease immunity is 
met (Plotkin 2008). Titers above 200 mIU/mL protect against infection whereas titers 
between 120-200 mIU/mL only protect from disease (Plotkin 2008). Therefore, the 
endpoints of a clinical trial or animal test determines what CoP must be met to 
determine success. 
    CoP Variables Based on Vaccine Characteristics. The properties of the 
vaccine itself also influence CoP, specifically their quality and ability to accurately 
measure. The challenge dose used for a clinical or animal trial affects CoP quality and 
quantity, so the dosage must be chosen carefully to induce a high enough quality CoP 
of a high enough quantity to achieve the desired endpoint (Plotkin 2008). For example, 
an attenuated polio vaccine blocked viral intestinal shedding in only 30% of vaccinees 
after high dose challenge despite blocking such shedding in 80% of vaccinees after low 
dose challenge (Onorato et al. 1991; Plotkin 2008). These results show that the dose of 
the vaccine induce enough immunity to protect the majority of people from small viral 
titer exposures, but not large viral titer exposures (Onorato et al. 1991; Plotkin 2008). 
Based on these data, the dosage should be increased, but considering that it is an 
attenuated polio vaccine, certain risks such as reversion to wild-type virulence come 





should be tested to determine which dosage, if any, both achieves the desired CoP and 
remains safe.  
Lack of NHP Animal Models. Current animal models used for HSV-2 vaccine 
candidates have certain limits in their similarity to HSV-2 pathogenicity in humans. No 
NHP models currently exist for HSV-2, which is problematic because vaccine 
candidate results in NHP usually better correlate with results in humans compared to 
results in mice (Dropulic and Cohen 2012). Unfortunately, vaccine candidates that 
looked promising in mice and/or guinea pigs failed in large-scale, expensive human 
trials.  
Mice, particularly the inbred BALB/c and C57BL/6 strains, are by far the most 
popular animal model for HSV-2 for their cost, short generation time, well-
characterized immune system, small size for easy handling, and smaller housing 
requirements (Dasgupta and BenMohamed 2011; Dropulic and Cohen 2012). Mice can 
be easily inoculated intravaginally after treatment with medroxyprogesterone, which 
thins the vaginal mucosa to facilitate successful infection (Dasgupta and BenMohamed 
2011; Dropulic and Cohen 2012). Blood, mucosa, and DRGs can be easily taken or 
harvested to measure antibody and cellular responses (Dropulic and Cohen 2012). 
These mice then develop acute disease, viral shedding, and latency in the DRG quite 
similarly to humans, so the mouse model yields good evaluation of potential 
prophylactic vaccine candidates’ effectiveness on preventing infection, acute disease, 
or latency (Dasgupta and BenMohamed 2011; Dropulic and Cohen 2012).  
Two major problems with mice, namely lack of spontaneous reactivation and 





Mice do not have spontaneous reactivation and subsequent disease episodes that 
humans do, so latently infected mice need to be stimulated with UV light or heat to 
induce reactivation (Dasgupta and BenMohamed 2011; Dropulic and Cohen 2012; 
LeBlanc et al. 1999; Sawtell and Thompson 1992). Therefore, mouse models are not 
useful for evaluating therapeutic vaccine candidates’ ability to prevent recurrent 
disease via long-lasting immune responses (Dasgupta and BenMohamed 2011; 
Dropulic and Cohen 2012). Intravaginal inoculation, the preferred method of injection 
for HSV-2 vaccine candidates, can lead to viral invasion of the sacral ganglia, causing 
bladder control loss, hind limb paralysis, and death (Dasgupta and BenMohamed 2011; 
Dropulic and Cohen 2012). Considering that HSV-2 does not cause these symptoms in 
humans during acute infection, chronic mouse HSV-2 pathogenesis and to a lesser 
extent acute pathogenesis do not mirror either of those in humans (Dasgupta and 
BenMohamed 2011).  
Guinea pigs are the gold standard small animal model for HSV-2 in part because 
they do have spontaneous reactivation of HSV-2 like humans do, so they are useful for 
evaluating the effectiveness of both prophylactic and therapeutic vaccines (Dasgupta 
and BenMohamed 2011; Scriba and Tatzber 1981; Stanberry et al. 1982; Stanberry et 
al. 1985; Stanberry 1991). During acute infection, guinea pigs shed virus and develop 
latency in the sacral and dorsal root ganglia, both of which can be measured to see if 
shedding is reduced or latency is prevented by the vaccine candidate (Dasgupta and 
BenMohamed 2011; Dropulic and Cohen 2012; Stanberry 1991). Antibody titers can 
be easily measured, but cellular responses in have not been well studied due to lack of 





2011; Dropulic and Cohen 2012). Considering that cellular responses are theorized to 
be important for controlling recurrent disease, the limitations on available immune 
reagents as well as a lack of knowledge of the guinea pig immune system hamper 
scientists’ ability to find CoPs responsible for blocking recurrent disease in a 
spontaneously reactivating model (Dasgupta and BenMohamed 2011).  
Cotton rats, rhesus macaques, and owl monkeys have also been used as models 
for HSV-2, but their usefulness is reduced compared to mice and guinea pigs for 
various reasons. Cotton rats have spontaneous reactivation and do not need 
medroxyprogesterone treatment before intravaginal inoculation, which confer two big 
advantages over mice (Yim et al. 2005). Despite cotton rates also having good acute 
HSV-2 infection and spontaneous reactivation, lack of immune reagents, lack of 
knowledge about their immune system, and their difficulty to work with has blocked 
any rise in their popularity as models (Dasgupta and BenMohamed 2011; Yim et al. 
2005). Rhesus macaques, a popular NHP model for many other diseases, unfortunately 
have low symptomatic infection rates with HSV-2, averaging about only 10% of 
animals developing lesions (Crostarosa et al. 2009: Dropulic and Cohen 2012). 
Therefore, rhesus macaques are not a practical model for HSV-2 considering the 
number of animals that would be needed per study to generate usable data, which would 
significantly increase the already expensive costs of NHP studies (Crostarosa et al. 
2009). On the other hand, owl monkeys develop lethal HSV-2 infections, which is 
beneficial for demonstrating live attenuated vaccine (LAV) safety (Melendez 1969; 





needed to kill off 50% of infected hosts, prevents them from being challenged with 
high doses that vaccine efficacy studies would require.  
Several factors about HSV-2 can explain why this lack of NHP animal models 
exists and why the smaller animal models of mice and guinea pigs do not always 
provide an accurate prediction of a vaccine candidate’s efficacy in humans. HSV-2 as 
well as the other human herpesviruses have coevolved with humans for millions of 
years, so the virus has specifically adapted to evade the human immune system, which 
leads to immune response discrepancies in animal models (Ellerman-Eriksen 2005; 
Dropulic and Cohen 2012; Grinde 2013). The one challenge model used in animal 
studies also does not mirror the multiple exposures that humans have over their 
lifetimes, so little information is known about vaccine candidates’ ability to induce 
long-lasting immunity to protect from infection years after immunization (Dropulic and 
Cohen 2012). However, to do long-term studies to study memory immune responses 
and antibody titers over time would be quite expensive due to the number of animals 
needed, extended housing and veterinary care needs, and potentially more personnel 
needed to run experiments and analyze data (Dropulic and Cohen 2012). Additionally, 
animals are challenged at their highest immune response to the vaccine candidate, 
which is a highly unlikely scenario to happen in humans (Dropulic and Cohen 2012).     
HSV-2’s evolved specificity to evade a single species’ immune system has led 
to several consequences for the virus itself as well as our inability to create a HSV-2 
vaccine. This specificity means that HSV-2 has a narrow host range as seen in its 
inability to cause significant disease in rhesus macaques, which has prevented 





cannot be used in challenge studies of new vaccine candidates with unknown safety 
profiles, so new vaccine candidates must be tested in inbred mice or guinea pigs. 
However, these two models have substantial differences in their innate, mucosal, and 
adaptive immune systems including different major histocompatibility complexes 
(MHC) alleles and mucosal immune cell distribution compared to outbred humans 
(Dasgupta and BenMohamed 2011; Dropulic and Cohen 2012). HSV-2’s immune 
evasion proteins such as ICP47, which downregulates MHC Class I, and gE, which 
binds to human IgG Fc, have significantly more activity in humans compared to mice, 
which can falsely amplify their effectiveness (Ahn et al. 1996; Johansson et al. 1985). 
Since guinea pig T cells cannot identify human leukocyte antigen (HLA)-restricted T 
cell epitopes, this model cannot be used to evaluate any HSV-2 T-cell-based vaccines 
unless transgenic guinea pig strains are created (Dasgupta and BenMohamed 2011).    
Finally, vaccine viruses are replicated in cell culture where they may acquire 
attenuating mutations, further diverging them from the non-attenuated HSV-2 strains 
that circulate in humans (Szpara et al. 2010). HSV-2 is mainly grown in the African 
green monkey kidney cell line Vero since it has been approved to grow vaccine viruses 
and produce other biologics for use in humans (Barrett et al. 2009). Since this cell line 
is not human, vaccine viruses may acquire mutations specific to promote replication 
and downregulate antiviral states in Veros which could impact their ability to elicit 
immune responses in humans (Dropulic and Cohen 2012). 
Subunit, Whole Virus Inactivated, and Replication-Defective HSV-2 Vaccines. Almost 
all previous HSV-2 vaccine candidates have been subunit protein vaccines, usually 





which are crucial for virus attachment and fusion to cells, respectively (Chentoufi et al. 
2012; Zhu et al. 2014). These two glycoproteins are also the two most highly antigenic 
HSV proteins, which make them desirable as vaccines as they can induce high 
neutralizing antibody titers and CD4+ and CD8+ T cell responses, which as discussed 
before can usually confer immunity (Chentoufi et al. 2012; Cohen et al. 1984; Kim et 
al. 2008; Kohl et al. 2000; Zhu et al. 2014). The popularity of these subunit vaccines 
stems from their obvious safety advantages since protein vaccines cannot accidentally 
infect and are extremely unlikely to harm vaccines (Chentoufi et al. 2012; Dropulic and 
Cohen 2012; Zhu et al. 2014). Also, the high similarity shared between both HSV-1 
and HSV-2’s gB and gD glycoproteins hopefully could lead to cross-protection after 
vaccination (Chentoufi et al. 2012; Dropulic and Cohen 2012).  However, none of these 
subunit vaccines adequately protected trial participants from HSV-2 acquisition or 
disease, which clearly indicates that other vaccine strategies for HSV-2 should be 
investigated as well (Chentoufi et al. 2012; Dropulic and Cohen 2012; Zhu et al. 2014).  
Whole virus and replication defective vaccine candidates have different 
benefits and disadvantages compared to subunit vaccines. These two types of HSV-2 
vaccines are not nearly as popular as subunit vaccines primarily for safety concerns, 
but they do offer key advantages that may help them become more widely considered 
as viable HSV-2 vaccine options as vaccine production quality standards have 
tightened and virus manipulation techniques continue to evolve. Few whole virus HSV-
2 vaccines have been made for HSV-2, primarily due to concerns that inactivation 
methods would not completely inactivate all virions and allow viable virions to 





The same concern stands for replication defective vaccines, which use virions 
that are incapable of completing more than one round of replication due to mutation or 
deletion of essential viral genes (Dropulic and Cohen 2012; Zhu et al. 2014). If these 
virions reverted back to wild-type, the vaccine virus could infect vaccinees instead of 
protecting them from infection although this risk is mitigated via complete or at least 
partial deletion compared to simple point mutations. However, whole virus and 
replication-defective vaccines present the entire repertoire of viral epitopes to the 
immune system instead of just one or two glycoproteins (Dropulic and Cohen 2012; 
Zhu et al. 2014). Considering that studies have found antibodies and T cells responses 
to other surface glycoproteins, tegument and capsid proteins, and viral DNA replication 
machinery proteins, exposing the immune system to many epitopes as opposed to just 
one or two may elicit combinations of immune responses that protect or reduce disease 
(Dropulic and Cohen 2012; Koelle et al. 1998; Koelle et al. 2001; Laing et al. 2010; 
Zhu et al. 2007; Zhu et al. 2014). Replication-defective vaccines further this benefit by 
undergoing at most a single round of replication, which can elicit a more robust immune 
response (Dropulic and Cohen 2012).     
 Subunit Vaccines. Previous subunit HSV-2 trials have mainly been a mixture of 
gD. gB, and various adjuvants to try to induce a potent enough immune response to 
protect from infection and disease (Chentoufi et al. 2012; Zhu et al. 2014). While many 
of these subunit vaccines looked promising in animal models, all of them have failed 
to meet their specified endpoints in human clinical trials, suggesting that one or two 
glycoproteins may not be enough to elicit protective immune responses (Chentoufi et 





explanation is needed in regards to specific glycoprotein names: glycoproteins from 
HSV-2 are denoted with a 2 after the letter (gD2) whereas those from HSV-1 are 
denoted with a 1 (gD1). 
 In the 1980s and 1990s, different combinations of multiple viral proteins and 
glycoproteins were tested as both prophylactic and therapeutic vaccines. A double-
blind study of a therapeutic vaccine candidate consisting of DNA-free viral antigens 
isolated from infected human cells in symptomatic individuals with frequent outbreaks 
showed that this vaccine not only induced poor immunity but also did not significantly 
decrease disease in these individuals compared to controls despite being highly 
immunogenic in animals (Dropulic and Cohen 2012; Kutinová et al. 1988). Another 
subunit vaccine composed of gB2, gC2, gD2, gE2, and gG2 purified from infected 
chick embryo fibroblasts (CEFs) was tested for its ability to protect HSV-2 
seronegative people in HSV-2 serodiscordant couples where their partners had frequent 
recurrent HSV-2 lesions (Dropulic and Cohen 2012; Mertz et al. 1990). This double-
blind, placebo-controlled clinical trial showed that the HSV-2 seronegative partners 
were not significantly protected from developing genital herpes compared to placebo 
(Dropulic and Cohen 2012; Mertz et al. 1990); vaccinees’ antibody titers to gD and gB 
were very low compared to their partners’, suggesting that the lack of protection from 
transmission may have been due to insufficient antibody titers (Dropulic and Cohen 
2012; Mertz et al. 1990). Another vaccine candidate made with formalin-inactivated 
HSV-1 glycoproteins extracted from cells did not reduce outbreak frequency in 
individuals with frequent recurrent genital outbreaks, but did statistically significantly 





These studies all suggested that viral proteins alone were unable to induce sufficient 
immunity, so future subunit vaccine candidates needed adjuvants (Dropulic and Cohen 
2012). 
 As mentioned above, more recent HSV-2 subunit vaccine candidates use gD, 
gB, and different adjuvants such as MF59 and aluminum hydroxide (alum), which can 
be combined with other adjuvants such as monophosphoryl lipid A (MPL), to boost 
immune responses (Zhu et al. 2014). Even with these adjuvants, subunit gD and gB 
vaccine candidates have not been successful in humans, suggesting that additional 
immune boosting techniques are needed (Chentoufi et al. 2012; Dropulic and Cohen 
2012; Zhu et al. 2014). A second adjuvant could be added to a vaccine candidate, 
though having two or more adjuvants does not seem to be common in at least previous 
vaccine candidate studies. Chemical interactions between two or more adjuvants 
potentially could cause problems either with safety of the vaccine formula, stability of 
the antigen proteins, or the composition and magnitude of the immune response. 
However, if adjuvant combinations can be certified as safe and immunogenic, they 
could be utilized to boost subunit vaccine efficacy since due to their safety, subunit 
HSV-2 vaccines will continue to remain popular. 
The most probable reason why no subunit gD and gB vaccine has met endpoints 
in human trials is inclusion of only one or two epitopes of a complex virus that encodes 
over eighty proteins, which probably has prevented the needed range of both humoral 
and cellular immune responses for sterilizing immunity or disease protection (Dropulic 
and Cohen 2012; Zhu et al. 2014). Studies have shown that HSV-2-specific CD4+ and 





capsid proteins (Dropulic and Cohen 2012; Koelle, Frank, et al. 1998; Koelle et al. 
2001). CD8+ T cells are responsible for destroying infected host cells, so a vaccine that 
contains multiple popular viral proteins recognized by CD8+ T cells would elicit a 
robust adaptive cell-mediated immunity as these CD8+ T cells would recognize many 
HSV-2 peptide fragments displayed on MHC Class I molecules of infected host cells. 
One study by found that 40% and 20% of HSV-2 seropositive individuals had T cells 
that recognized gD and gB, respectively, which shows that while these two surface 
glycoproteins were widely recognized by T cells, these people still were not protected 
from disease (Posavad et al. 2010). However, HSV-2 immune seronegative (IS) 
individuals, or people who has no signs of HSV-2 infection but show HSV-2 specific 
T cell activity, had high percentages of HSV-2 T cells that recognized IE proteins such 
as UL39, ICP0, and ICP4 (Posavad et al. 2010); few IS individuals had T cells that 
recognized either gD and gB (Posavad et al. 2010). This distinct skewing of recognized 
T cell epitopes between HSV-2 seropositive and IS individuals strongly suggests that 
T cells that recognize IE proteins are more important for protection from infection than 
T cells that recognize gD or gB (Dropulic and Cohen 2012; Posavad et al. 2010). 
These CD4+ T cells would activate B cells that also recognize these more 
hidden epitopes. These interior viral proteins are expressed earlier in the viral lifecycle, 
so T cell responses to these IE proteins may be more effective in controlling viral 
replication as they would stop viral downregulation of immunity and host cell 
translation (Braun, Payne, and Dong 2006). This logic is supported by a study by 
Braun, Payne, and Dong that found that higher CD4+ T cell responses to IE proteins 





(Braun, Payne, and Dong 2006). In contrast, higher CD4+ T cell responses to gD 
correlated to high recurrence HSV-2 seropositive individuals (Braun, Payne, and Dong 
2006). Therefore, gD2-specific CD4+ T cells do not seem to protect against disease at 
all (Braun, Payne, and Dong 2006). Subunit vaccines that only contain surface antigens 
that are mainly produced late in the viral lifecycle will not activate T and B cells that 
recognize these interior viral epitopes that would be able to shut off viral replication 
earlier.  
A prophylactic vaccine candidate of gD2 and gB2 in adjuvant MF59, a 
squalene-containing oil-in-water emulsion, was tested in two randomized, double-
blind, placebo-controlled studies in which HSV-2 seronegative partners of 
serodiscordant couples and attendees of a STI clinic at high risk for HSV-2 infection 
(Corey et al. 1999; Dropulic and Cohen 2012). While vaccinees’ HSV-2 infection rate 
was 50% lower than controls five months post-vaccination, this protection was 
undetectable one year post-vaccination and thus indicated that this vaccine candidate 
did not evoke long-lasting immunity (Corey et al. 1999; Dropulic and Cohen 2012). 
No reduction in symptomatic HSV-2 disease was seen despite the vaccine candidate 
inducing higher neutralizing antibody titers than natural infection, strongly suggesting 
that antibody titers alone cannot protect against infection (Corey et al. 1999; Dropulic 
and Cohen 2012). Pre-existing HSV-1 immunity did not reduce HSV-2 acquisition rate, 
but did increase the number of asymptomatic HSV-2 infections, confirming that some 
immune cross-protection exists between HSV-1 and HSV-2, which would be expected 
considering their high level of similarity of 83% identity in genomic coding regions 





Another prophylactic vaccine candidate of gD2 with alum-MPL was tested in 
two populations of HSV-1/HSV-2 double seronegative individuals or women with any 
HSV serostatus whom had partners with genital herpes (Dropulic and Cohen 2012; 
Stanberry et al. 2002). Neither population was protected from genital disease, showing 
38% and 42% efficacy, respectively (Dropulic and Cohen 2012; Stanberry et al. 2002). 
Interestingly, subanalyses of the vaccine indicated 73% and 74% efficacy in these two 
populations in preventing disease in double seronegative women, but not in HSV-1 
positive/HSV-2 negative women or in men with any HSV serostatus (Dropulic and 
Cohen 2012; Stanberry et al. 2002). Perhaps the preexisting immune response to HSV-
1 precluded a robust enough immune response to protect against HSV-2 (Coleman and 
Shukla 2013). Another reason could be that anti-HSV-1 antibodies and T cells do not 
have high enough cross protection with HSV-2 despite high similarity between the 
viruses to adequately protect, indicating that maybe these anti-HSV-1 immune 
responses target very specific epitopes that are not shared between HSV-1 and HSV-2. 
The fact that no men were protected suggests that vaginal mucosal immunity was 
important for protecting double-seronegative women as all men would not have such 
mucosal surfaces where anti-HSV antibodies could be deposited to intercept virions 
contacting the mucosal surface (Coleman and Shukla 2013).  
This same gD in alum-MPL formulation was tested in a large scale clinical trial 
(Herpevac) in over 8000 double seronegative women because the results from the 
previous study showed high efficacy in preventing HSV-2 disease in this population 
(Belshe et al. 2012). Vaccinees presented high antibody titers and CD4+ T cell 





or infection, indicating that these anti-gD2 responses were unable to protect from 
infection or disease and further suggesting that exposing the immune system to more 
epitopes of the virus is necessary to induce a protective immune response (Belshe et al. 
2012; Dropulic and Cohen 2012).  
This discrepancy between the two trials has not been fully explained, though 
differences in the test populations may be to blame as the first trial had women whose 
partners had confirmed genital herpes whereas the Herpevac trial only had women 
deemed at risk for HSV infection and disease (Belshe et al. 2012). Perhaps the first trial 
showed efficacy because these women most definitely had repeated exposures to HSV-
2 either from symptomatic outbreaks or subclinical shedding (Belshe et al. 2012; 
Dropulic and Cohen 2012). These repeated exposures may have boosted the vaccine’s 
effectiveness since vaccinees were most likely challenged soon after vaccination during 
peak immune response and repeated challenges maintained higher levels of antibody 
and T cells (Belshe et al. 2012; Dropulic and Cohen 2012). Therefore, its ability to 
generate long-lasting immunity despite infrequent exposures was unable to be critically 
evaluated (Dropulic and Cohen 2012). Women in the Herpevac trial may not have been 
challenged as soon after vaccination, so if the vaccine was not able to generate a robust 
memory response, they would not be protected from infection or disease when 
challenged months or years after vaccination (Dropulic and Cohen 2012). Interestingly, 
the vaccine did show a 35% reduction in infection and 58% reduction in genital disease 
caused by HSV-1, which was the more common etiologic agent of genital herpes in the 





 Whole Virus Inactivated Vaccines. Whole virus vaccines were popular in the 
1940s to 1960s, but problems with inactivation, poorly controlled studies, and lack of 
positive results have severely reduced whole virus HSV-2 vaccine candidate 
production (Dropulic and Cohen 2012). Whole virus was grown in fertilized eggs or 
cell culture, which unfortunately could introduce attenuating mutations into vaccine 
viruses which may change epitopes (Dropulic and Cohen 2012). The three methods of 
inactivation – heat, chemicals like formaldehyde or formalin, and UV light – run the 
risk of not fully inactivating all virions (Dropulic and Cohen 2012). In 1964, the first 
double-blind, randomized, placebo-controlled trial for a HSV-2 vaccine was conducted 
by vaccinating individuals with recurrent disease with formaldehyde-inactivated whole 
virus (Dropulic and Cohen 2012; Kern and Schiff 1964). Unfortunately, reduction in 
lesions in vaccinees and the placebo group was similar, indicating that this therapeutic 
vaccine candidate failed (Dropulic and Cohen 2012; Kern and Schiff 1964). No other 
properly controlled, double-blinded studies have been done for inactivated whole virus 
vaccines (Dropulic and Cohen 2012). However, inactivated vaccines should be 
revisited as an option if formulated with newer, more immunogenic adjuvants.   
Replication-Defective Vaccines. Live HSV-2 vaccines have garnered more 
attention with the development of the replication defective dl5-29 virus, a HSV-2 strain 
with the essential UL5 and UL29 ORFs deleted (Da Costa et al. 2000; Hoshino et al. 
2005). This replication-defective strain cannot undergo a full round of replication in 
the host, limiting the possibility of latency establishment while still evoking a 
protective immune response (Da Costa et al. 2000; Hoshino 2005). Viral stocks are 





eliminates the manufacturing concern that this vaccine virus would be difficult to mass-
produce (Da Costa et al. 2000).  This vaccine candidate has reduced latency capacity 
in both mice and guinea pigs (Da Costa, Jones, and Knipe 1999; Hoshino 2005). Both 
vaccinated mice and guinea pigs had less viral shedding and better survival when 
challenged with wild-type HSV-2 (Da Costa, Jones, and Knipe 1999; Hoshino 2005). 
Guinea pigs vaccinated with this vaccine candidate also were better protected from 
wild-type HSV-2 challenge compared to those vaccinated with gD, showing higher 
neutralizing antibody titers, fewer HSV-2 genomes in DRGs, and less viral shedding 
(Hoshino et al. 2009). Currently this vaccine candidate is undergoing a clinical trial in 
humans.    
Other studies on different ways to attenuate HSV-2 have been published, such 
as deleting part or all of certain immune evasion genes such as ICP0, which inhibits the 
interferon response, or mutating crucial residues on gD that prevent the virus from 
binding nectin-1, the receptor it uses to enter neurons (Halford et al. 2011; Wang et al. 
2012). While these methods have produced viable attenuated potential vaccine 
candidates, other attenuation methods should be investigated, especially those that 
preserve as many epitopes as possible.  
Live Attenuated HSV-2 Vaccines. Live attenuated vaccines (LAVs) have been licensed 
for varicella, influenza, measles/mumps/rubella (MMR), rotavirus, polio, and vaccinia 
(Minor 2015). LAVs usually give a more potent, durable, and complete immune 
response since the vaccine virus still replicates in the vaccine recipient and possesses 
all the potential epitopes that the immune system would encounter during a natural 





licensed, available human herpesvirus vaccine currently available is an attenuated Oka 
strain of varicella-zoster, LAVs for other herpesviruses like HSV-2 should be seriously 
considered (Dropulic and Cohen 2012; Yamanishi 2008).  
 Recent data of HSV-2 LAV candidates in mice further recommend LAVs as a 
viable choice for HSV-2 vaccines. Different immune evasion genes such as ICP0 or 
genes necessary for viral spread like gE have been deleted to generate LAV candidates 
(Halford et al. 2011; Wang et al. 2012). ICP0 is an interferon antagonist, so by partially 
deleting certain domains like the nuclear localization signal (NLS) would make a strain 
that is less able to evade host immune responses (Halford, Püschel, and Rakowski 
2010). Halford and colleagues deleted the NLS from ICP0 from HSV-2 (ICP0ΔNLS) 
to test its ability to protect mice from lethal challenge after intraocular or intravaginal 
challenge (Halford, Püschel, and Rakowski 2010). Both intraocularly and 
intravaginally ICP0ΔNLS-vaccinated mice with this strain were protected from lethal 
challenge (Halford, Püschel, and Rakowski 2010); intravaginally ICP0ΔNLS-
vaccinated mice were better protected from mortality, generated higher neutralizing 
antibody titers, and had reduced vaginal shedding compared to mice vaccinated with 
gD2 in alum+MPL (Halford et al. 2011). Considering that severely 
immunocompromised mice died after vaccination with ICP0ΔNLS, ICP0ΔNLS is not 
attenuated enough to bring to clinical trials (Halford, Püschel, and Rakowski 2010). 
Other attenuation methods should be used on ICP0ΔNLS to further attenuate it such as 
deletion of more immune evasion genes like ICP47, which inhibits MHC Class I 





Despite previous success in mice, LAVs for HSV-2 have not been seriously 
considered due to the risk that the vaccine virus will still be able to establish latency in 
the neurons of vaccine recipients and potentially reactivate and expose their intimate 
partners (Dropulic and Cohen 2012). Therefore, any live attenuated HSV-2 vaccine 
candidates must be subjected to rigorous safety testing to ensure these viruses replicate 
sufficiently to induce a protective immune response, but are unable to replicate to high 
enough titers or are unable to infect neurons to establish latency (Dropulic and Cohen 
2012). If completely preventing latency is unattainable, having a vaccine strain 
establish latency would be acceptable as long as it does not cause disease in vaccinees.   
Current LAVs for HSV-2 have only utilized common attenuation methods of 
missense mutations or deletions of viral genes. Despite their demonstrated ability to 
attenuate viruses, both missense and deletion mutations pose some problems that 
potentially could impact the effectiveness of vaccine candidates made using these 
mutations. Missense mutations can potentially revert to wild-type, especially if made 
in genomic areas of high variability or in essential protein moieties; however, this 
concern is somewhat lesser for DNA viruses such as HSV-2 compared to RNA viruses, 
which on average have higher mutation rates. Missense mutations also may change 
epitopes, which may prevent the resultant immune response from being able to 
recognize wild-type viral exposures. For example, Wang and colleagues formulated a 
HSV-2 gD mutant (HSV-2 gD27) that has three point mutations at amino acids 215, 
222, and 223 to ablate nectin-1 but not HVEM binding so the virus can still lytically 
replicate in epithelial cells but not infect and establish latency in neurons (Wang et al. 





crucial, mutating these residues may destroy epitopes that if recognized by the immune 
system during wild-type, nectin-1-binding-competent HSV-2 natural infection, may 
prevent latency. Full or partial deletions of genes are safer as the chance of reversion is 
much lower, but they completely remove or more severely distort epitopes compared 
to missense mutations. Therefore, preserving as many epitopes as possible between the 
wild-type and vaccine strains is crucial, so attenuation methods such as codon bias 
deoptimization (CBD) and codon pair bias deoptimization (CPBD) should be more 
frequently used to make LAV candidates for both viral and bacterial pathogens.  
Section 5: Codon Pair Bias Deoptimization 
Codon Pair Bias Deoptimization (CPBD) As An Attenuation Method. Codon bias (CB) 
and codon pair bias (CPB) have been observed in many sequenced genomes. Both such 
phenomena are possible due to the degeneracy of the genetic code whereas multiple 
codons can encode the same amino acid. CB refers to the phenomenon that certain 
codons for a particular amino acid are used more frequently than expected by chance 
(Buchan, Aucott, and Stansfield 2006). For example, the codons UCU and UCC both 
encode serine, but in a specific genome, the codon UCU is used significantly more 
often than UCC to code for serine in polypeptides (Coleman et al. 2008). CPB refers to 
the fact that certain codons are found next to each other in pairs more often than 
expected by chance (Buchan, Aucott, and Stansfield 2006; Coleman et al. 2008). For 
examples, the codon pairs UCUGUU and UCCGUU encode the dipeptide serine-
valine, but UCUGUU is used significantly more frequently to encode serine-valine than 
UCCGUU. Different species and viruses exhibit different CBs and CPBs (Boycheva et 





Hatfield 1989; Moura et al. 2005). Both CB and CPB have been shown to affect 
translational elongation rates and fidelity in vivo (Buchan, Aucott, and Stansfield 2006; 
Curran et al. 1995; Irwin et al. 1995; Folley and Yarus 1989; Smith and Yarus 1989).  
The CPBs of pathogen genomes can be taken advantage of by a relatively new 
method called synthetic attenuated virus engineering (SAVE) first described by 
Coleman and colleagues for polio (Coleman et al. 2008). SAVE identifies the CPB of 
viral genomes and then recodes them by substituting rarely used codon pairs in for 
frequently used codon pairs without changing the amino acid sequence (Coleman et al. 
2008). SAVE therefore can make hundreds of silent mutations throughout a viral 
genome without disrupting or altering potential epitopes, a process called codon pair 
bias deoptimization (CPBD) (Coleman et al. 2008). Therefore, any potential vaccine 
virus made with SAVE would theoretically induce the same humoral and cellular 
immune response as a wild-type strain (Coleman et al. 2008). The vast number of 
mutations also drastically reduces the chance for reversion, making CPBD a safe 
attenuation method (Coleman et al. 2008). SAVE can quickly analyze viral genomes 
to generate deoptimized sequences, which then can be customized according to 
researchers’ wishes on how much and what parts of the genome should be deoptimized 
(Coleman et al. 2008).  
The mechanism of attenuation of SAVE and CPBD is currently unknown 
(Wang et al. 2015). Problems with transcription and/or translation of the deoptimized 
genome could contribute to the attenuated phenotype of pathogens. Transcription 
issues could include decreased ability of the template to bind transcription factors and 





polymerase; inability to modify the mRNA in certain ways such as capping or 
polyadenylation; and other issues stemming from the presumably very different 
secondary structures formed by different chemical interactions due to the many 
nucleotides changes in the deoptimized mRNA (Wang et al. 2015). A recent study by 
Tulloch and colleagues claims that changes in CpG and UpA dinucleotide frequencies 
make viral pathogens more recognizable by the cell’s anti-viral defenses, which 
prevents the virus from replicating (Tulloch et al. 2014); therefore, defects in 
replication not due to decreased viral fitness but to increased recognition by host cells 
may also be at play (Tulloch et al. 2014). Another recent study with codon pair recoded 
dengue virus also supports this mechanism of attenuation (Simmons et al. 2015).  
Translation issues mainly would stem from differences in tRNA concentrations, 
which is currently the prevailing idea of how SAVE attenuates pathogens (Wang et al. 
2015). Frequently used codon pairs would have higher concentrations of their 
corresponding tRNAs whereas rarely used codon pairs would have lower 
concentrations, so translation of the deoptimized mRNAs would take longer and not 
produce as many protein products compared to wild-type mRNA, thus leading to the 
attenuated phenotype (Wang et al. 2015). Considering significantly reduced levels of 
corresponding deoptomized proteins by Western blot were seen in two studies, a defect 
in translation is probably at least contributing to the attenuated phenotype of CPBD 
pathogens (Mueller et al. 2010; Yang et al. 2013). Based on the current compilation of 
data, the mechanism of attenuation is probably a combination of all these factors.     
Previous Literature on CPBD Human Pathogens. Considering that SAVE and CPBD 





successfully attenuate human pathogens and protect animals from challenge. The first 
paper published describing SAVE by Coleman and colleagues in 2008 deoptimized 
parts of the polio genome to create different “Min” viruses to characterize in vitro and 
in vivo (Coleman et al. 2008). These “Min” viruses had 0.5 to 3 log lower titers than 
wild-type polio when grown in cell culture (Coleman et al. 2008). Two “Min” viruses 
were tested for safety and protection in mice; “Min” viruses had a 10 fold higher 50% 
paralysis lethal dose (PLD50), or the amount of virus needed to paralyze 50% of the 
mice, indicating an observable attenuated phenotype in vivo (Coleman et al. 2008). 
Mice vaccinated with these “Min” viruses were protected from paralysis and death 
when challenged with a lethal dose of wild-type polio, showing proof of concept that 
viruses deoptimized with SAVE could generate successful vaccines even for RNA 
viruses which have higher mutation rates (Coleman et al. 2008).  
SAVE’s ability to attenuate influenza has been evaluated in two papers. Mueller 
and colleagues deoptimized the PB1, HA, and NP influenza genes of the H1N1 PR8 
lab strain to generate the resultant PB1min, NPmin, HAmin, and PB1/NP/HAmin PR8 
viruses, which grew to 10-fold less end-titers in vitro (Mueller et al. 2010). PB1 is one 
of the three subunits of the viral RNA polymerase, HA is the surface spike protein 
hemagglutinin that aids in viral attachment and fusion, and NP is the nucleoprotein that 
packages the viral RNA genome (Mueller et al. 2010). The rationale for deoptimizing 
these three genes was to target different stages of the viral lifecycle – attachment for 
HA, genome replication and transcription for PB1, and genome packaging for NP – to 
see if crippling different stages led to more severely attenuated phenotypes (Mueller et 





The comparable end-titers between the deoptimized and wild-type influenza 
viruses show good manufacturing potential (Mueller et al. 2010). Western blots of the 
corresponding deoptimized proteins showed significantly decreased concentrations, 
which suggests that the mechanism of attenuation of CBPD is at least in part due to 
defects in translation (Mueller et al. 2010). Mice infected with the triple deoptimized 
PR8 virus did not die or exhibit weight loss through 16 days post-infection (DPI) 
whereas mice infected with wild-type PR8 all died before 6 DPI, showing that the triple 
deoptimized virus was safe and did not cause symptoms in mice (Mueller et al. 2010). 
Lung samples of the mice infected with the triple deoptimized virus had a peak titer of 
105.5 PFU/mL at day 3 post-infection compared to the wild-type PR8’s peak titer of 108 
PFU/mL (Mueller et al. 2010); this discrepancy in peak titers shows that the triple 
deoptimized virus does not replicate as well as the wild-type, so it was cleared faster 
by the murine immune system (Mueller et al. 2010).  
A later paper by Yang and colleagues showed that a double deoptimized H1N1 
PR8 virus with both spike proteins of hemagglutinin and neuraminidase (NA) 
deoptimized had significantly less HA protein and NA RNA at 6 hours post-infection 
(HPI), which now suggests that maybe the mechanism of attenuation for CPBD is due 
to defects in both transcription and translation (Yang et al. 2013). Interestingly, mice 
vaccinated with this HA/NAmin virus were somewhat protected from heterologous 
challenge with two H3N2 strains, A/Aichi/2/1968 and A/Victoria/3/75 (Yang et al. 
2013); these mice had less weight loss and lower mortality rates than unvaccinated 
mice which correlated to higher vaccination doses of the HA/NA min virus (Yang et 





similarity between their HA and NA proteins, it is intriguing that this PR8 HA/NAmin 
vaccine would elicit cross-protective antibodies that would recognize heterologous 
strains (Yang et al. 2013). Perhaps these two proteins were somehow degraded, 
allowing the murine immune system to recognize cryptic and conserved epitopes, 
especially of the HA stem, which could explain the vaccine’s low cross 50% protective 
dose (PD50) of 147 PFU/mL against A/Aichi/2/1968 and 237 PFU/mL against 
A/Victoria/3/75 (Yang et al. 2013). These data indicate that vaccine candidates made 
with SAVE could potentially confer cross-protection to heterologous challenge, which 
would be ideal for pathogens such as influenza that have myriad strains that undergo 
antigenic drift and antigenic shift.  
A paper published in 2013 by Martus and colleagues studied SAVE’s effect on 
HIV, whose extremely high mutation rate might overcome the attenuating effect of 
SAVE’s many silent mutations through rapid reversion. A HIV virus with its entire gag 
protein deoptimized was attenuated in MT-4 cells, a human T cell line that is very 
sensitive to HIV infection, and peripheral blood mononuclear cells (PBMCs), which 
include lymphocytes and monocytes (Martus et al. 2013). However, almost all isolates 
of six deoptimized HIV virus strains recovered wild-type replication capacity after 15 
serial passages in MT-4 cells; deoptimized isolates showed a 1.5 to 12-fold higher 
mutation frequency compared to wild-type HIV (Martus et al. 2013). Sequencing 
revealed multiple deoptimizing mutations reverted to wild-type as well as incorporation 
of nonsynonymous mutations that mitigated the negative CPB of the viral genes 





to the concern that the vaccine virus could revert to wild-type in the host to cause 
disease rather than induce immunity.    
A recent study on four codon pair deoptimized respiratory syncytial virus 
(RSV) vaccine candidates by Le Nouën and colleagues were attenuated in vitro and in 
vivo (Le Nouën et al. 2014).  The four deoptimized RSVs made were Min A, which 
had NS1, NS2, M, P, N, and SH genes deoptimized (Le Nouën et al. 2014); Min B, 
which had the G and F surface glycoprotein genes deoptimized; MinFLC virus, which 
was completely deoptimized except for the M gene; and Min L, which only had the L 
gene deoptimized (Le Nouën et al. 2014). Min FLC was the most temperature sensitive 
in vitro whereas Min B grew the least efficiently in vitro, indicating that deoptimization 
of the G and F genes were the most attenuating in vitro, probably because reduced 
surface glycoprotein concentrations led to incorrect molar ratios with other proteins, 
which could have generated less infectious virions capable of successfully spreading in 
cell culture (Le Nouën et al. 2014). Levels of deoptimized gene mRNA and protein 
were reduced compared to wild-type RSV (Le Nouën et al. 2014).  
These deoptimized RSV vaccine candidates were tested in both mice and 
African green monkeys (AGMs). In BALB/c mice, only 1 mouse out of 5 mice had 
replicating MinA or Min L virus in their nasal turbinates compared to wild-type RSV 
1 and 5 DPI (Le Nouën et al. 2014); titers of these two viruses in the lungs were between 
2 to 10-fold lower compared to wild-type RSV on 1 and 5 DPI (Le Nouën et al. 2014). 
Min FLC did not replicate in either the nasal trubinates or lungs throughout the 
experiment (Le Nouën et al. 2014). In AGMs, significantly reduced viral shedding as 





for Min A, Min L, and Min FLC when compared to wild-type RSV (Le Nouën et al. 
2014). However, Min A and Min L vaccination induced similar antibody titers 
compared to wild-type RSV and all three Min viruses showed similar attenuation to 
two RSV strain currently in human clinical trials, suggesting that they could be used as 
vaccine candidates for humans (Le Nouën et al. 2014). 
While most of the limited papers on CPBD and SAVE have been on viral 
pathogens, this technology can also be applied to bacterial pathogens. Since the 
genomes of bacteria are usually much bigger than viruses, SAVE would potentially not 
be as cost-effective especially as the desired deoptimized percentage of the genome 
increases as deoptimized sequences must be customly synthesized according to the 
CPB of the organism. A Streptococcus pneumoniae paper from Coleman and 
colleagues deoptimized the pneumolysin gene, the protein product of which is a 
virulence factor for this species as it creates pores in target cells (Coleman et al. 2011). 
Mice vaccinated with this deoptimized strain had better survival against wild-type 
challenge, which can be attributed to their significantly higher antibody titers against 
whole bacteria, pneumolysin, and pneumococcal capsule lipopolysaccharide (Coleman 
et al. 2011). This paper shows proof of concept of CPBD and SAVE’s ability to 
successfully attenuate bacterial pathogens to create vaccine candidates. 
This method theoretically could attenuate protozoan and fungal human 
pathogens as well by deoptimizing virulence genes, though the number of fully or 
partially deoptimized virulence genes required to acquire an attenuated phenotype 
probably will vary between pathogens. Deoptimizing other genes required for cell wall 





transcription, translation, and protein modification probably would confer a more 
severely attenuated phenotype if there are safety concerns, but these strains might not 
grow well in vitro and thus would be difficult to upscale their manufacture. 
SAVE could also be used to attenuate animal pathogens to create veterinary 
vaccines, which would take less time to get to market as they are easier to license due 
to looser requirements for safety. A recent paper attenuated vesicular stomatitis virus 
(VSV), which is both a veterinary and human viral pathogen that typically causes 
gastrointestinal disease, by partially deoptimizing the N-terminal segment of the L 
polymerase gene (Coleman et al. 2015). This Lmin virus was nonviable in cell culture 
and produced very little L protein, showing that they overattenuated the virus and thus 
should not deoptimize as much of the L protein or deoptimize other genes instead 
(Coleman et al. 2015).        
Summary of Projects. No papers using CPBD and SAVE to attenuate DNA viruses 
have been published, so SAVE’s ability to attenuate DNA viruses is unknown. Given 
the previous failures of subunit HSV-2 vaccines in clinical trials and the fact that the 
only herpesvirus vaccine available is a LAV for varicella-zoster virus, LAVs for HSV-
2 should be more seriously considered. Therefore, this thesis seeks to create HSV-2 
LAV candidates by deoptimizing three essential viral genes – the polymerase (UL30) 
and two nuclear egress complex proteins (UL31 and UL34). These three genes were 
chosen because targeting genes important for viral genome replication and egress 
would maximize the possibility of generating an attenuated phenotype in the resultant 
mutants while still allowing full expression of other viral proteins. These deoptimized 





(BAC). Mutations will be made in this BAC by a two-step recombineering process 
called galK-DOG double selection (Warming et al. 2005). The galactose operon of E. 
coli contains galE, galT, galK, and galM which enable the cell to utilize galactose as 
an only carbon source (Warming et al. 2005); galK encodes galactokinase, which is 
responsible for phosphorylating galactose to galactose-1-phosphate to begin the 
galactose degradation pathway (Alper and Ames 1975; Warming et al. 2005). These 
three wild-type ORFs will be replaced by a galK cassette by homologous 
recombination, allowing transformants to be selected by growth on M63 minimal 
media with galactose. The galK cassettes will then be replaced with the CPBD genes 
using a 2-deoxy-galactose (DOG) selection to kill any galK-BAC-containing bacteria 
as galK catalyzes DOG into 2-deoxy-galactose-1-phosphate, a toxic intermediate 
compound that cannot be metabolized (Figure 4). Once the mutant viruses are rescued, 
their replication kinetics in multiple cell lines and their vaccine potential in mice will 
be characterized.  
 Mice will be monitored for primary infection symptoms such as lesion size, 
severity, number, and duration; hind limb paralysis; ruffled fur; lethargy; and death. 
Vaginal swabs will be analyzed by plaque assay to determine the titer of shedding virus. 
DRGs will be harvested for qPCR to quantify how many HSV-2 genomes established 
latency in the mice. Since mice do not have spontaneous reactivation like humans do, 
challenged mice should try to have reactivation induced to see how well the vaccine 
candidates reduce subsequent outbreak severity and duration. UV light has been used 
to reactivate latent ocular herpes, so perhaps UV light could also reactivate latent 





be repeated in guinea pigs to measure any effects on subsequent outbreak frequency, 
duration, and severity.  
 The CoP for HSV-2 are unknown, which makes vaccine development difficult 
in that researchers do not know what immune responses their vaccine candidates must 
induce to meet endpoints of infection prevention or disease reduction. Various 
monoclonal gD and gB antibodies (mAbs) have been shown to be effective at 
neutralizing HSV-2 in vitro and in vivo, suggesting that antibodies are important for 
preventing infection. First, literature 50% inhibitory concentration (IC50) values, or the 
amount of mAb needed to inhibit viral infection by 50%, for specific gD and gB 
monoclonal antibodies will be confirmed. Mice will be injected with different doses of 
these antibodies and challenged with wild-type HSV-2 to analyze how well these 
antibodies protected from infection and disease. The same tests described for CPBD 
mice studies will be done for these mice as well to determine latency, shedding, and 










Chapter 2: Methods 
Section 1: Basic Molecular Biology Techniques 
In accordance with proper sterile technique and BSL-2 safety rules, all 
protocols involving live cells and virus were completed in a certified biosafety cabinet 
with the researcher wearing a lab coat and gloves. Excess cells and unneeded virus 
were killed by submergence in a 10% bleach solution for at least 20 minutes. All used 
cell culture items such as flasks and plates were discarded in biohazard waste to be 
autoclaved. All large pipets used with pipet guns were disinfected in a Wescodyne 
solution prepared by autoclave staff.  
Eukaryotic Cell Culture. Media requirements for Vero cells were DMEM (Gibco) 
supplemented with 10% fetal bovine serum (FBS, HyClone) and 1% 100x Penicillin-
Streptomycin-Glutamine (PSG, Gibco). To start a new cell culture, one cryovial of 
Vero cells was flash-thawed in a bath of 37 oC water before being resuspended in either 
15 or 25 mL of pre-warmed 37 oC complete DMEM for a T75 or T175 flask, respectively. 
Flasks would be seeded at different confluencies as desired using the assumption that 
seeding 7 x 106 cells in a T75 flask and 1.2 x 10
7 cells in a T175 flask would result in 
100% confluency in 24 hours. Vero cells were split every 3 to 4 days to maintain 
adequate confluency. To split cells, complete DMEM, 0.05% trypsin (Gibco), and 1x 
PBS (Gibco) were pre-warmed in a 37 oC water bath. Complete DMEM would be 
removed from the flask with a 25 mL pipet and the flask would be washed once with 
10 mL 1x PBS to maximize trypsinzation efficiency. Then 5 mL of trypsin was added 





flask was tilted. Cells were resuspended by flooding them down the flask bottom with 
a 5 mL or 10 mL pipet multiple times until most cells were individual under the 
microscope. Then 0.1 mL of cells was added to 0.3 mL of complete DMEM to make a 
1:4 dilution. Fifteen microliters of cells were flooded onto a clean hemocytometer with 
a clean coverslip. Cells in the four 4x4 squares were counted, added up, and multiplied 
by 104 to determine cells/mL. Flasks were reseeded with the desired number of cells 
and made up to 25 mL with complete DMEM. Flasks were incubated at 37 oC, 5% CO2.   
Preparation of Cell-Free HSV-2 Viral Stocks. T175 flasks were seeded with 1.2 x 10
7 
Vero cells in 25 mL complete DMEM the day before infection and incubated at 37 oC, 
5% CO2 overnight. If flasks were not 100% confluent, they would be incubated at 37 
oC, 5% CO2 until they were. Complete DMEM was removed with pipet and 4 mL of 
fresh complete DMEM was added back to the flask. Flasks would be inoculated with 
different μL amounts of virus from a 1 x 107 PFU/mL HSV-2 viral stock depending on 
what multiplicity of infection (MOI) was desired. Flasks were incubated at 37 oC, 5 % 
CO2 for 1 hour with tilting every 15 minutes before 21 mL of complete DMEM was 
added to the flask. Flasks were incubated at 37 oC, 5% CO2 for two days or until when 
100% cytopathic effect (CPE) was observed. Cells were removed from the flask bottom 
with a cell scraper and transferred to a 50 mL Falcon tube. If the rest of the protocol 
could not be immediately completed, the 50 mL Falcon was thoroughly vortexed before 
storing at -80 oC. Cells were spun at 800 rpm at 4 oC for 5 minutes. Media was aspirated 
off pellet until 3 mL were left and the remaining media and pellet were immediately 
frozen on dry ice. Tube was thawed in a 37 oC water bath for 2-3 minutes before being 





freeze-thawed 3 times before spun at 2000 rpm at 4 oC for 10 minutes. Supernatant was 
transferred to new 50 mL Falcon and transferred to cryovials in 0.2-0.5 mL aliquots. 
Aliquots were frozen on dry ice and stored at -80 oC.    
Plaque Assay. Plaque assays were stained using crystal violet, which was made in 1 L 
batches by combining 100 mL formaldehyde, 50 mL acetic acid, 600 mL methanol, 
250 mL water, and 10 g crystal violet powder in a chemical fume hood. The appropriate 
number of 6-well plates were seeded at 5 x 105 cells/well in 2.5 mL complete DMEM 
per well and incubated at 37 oC, 5% CO2 the day before infection. Complete DMEM 
media was aspirated via low-power vacuum pipetting from all wells. The first well had 
550 μL of complete DMEM added and all other wells had 500 μL complete DMEM 
added. Then 5.5 μL of HSV-2 viral stock would be added to the first well to create a 
1:100 (10-2) dilution that was mixed by either pipetting up and down or tilting the plate 
back and forth. Then 55 μL from this well would be added to the next well and mixed 
to create a 1:1000 (10-3) dilution. This process was repeated for all wells with a new 
pipet tip to prevent inaccuracy in the 1:10 dilution scheme ranging from 10-2 to 10-7. 
After the complete DMEM in the last well was mixed with 55 μL from the previous 
well, 55 μl would be discarded from the last well. All infected plates would be 
incubated at 37 oC, 5% CO2 for 1 hour with tilting every 15 minutes to ensure adequate 
viral contact with the Vero cell monolayer. During incubation, overlay medium 
containing human γ-globulin (intravenous immunoglobulin, IVIG) was made by 
adding 2.5 μL 10% IVIG per mL of complete DMEM needed. Viral inoculum was 
aspirated via low-power vacuum pipetting and 2.5 mL overlay medium per well was 





for 2 days at 37 oC, 5% CO2. Overlay media was aspirated via low-power vacuum 
pipetting and at least 1 mL of crystal violet solution was immediately added to wells. 
All plates were incubated at room temperature (RT) for 1 hour. Plates were washed by 
repeatedly carefully submerging them in cold water and lifting them until water ran 
clear. Plates were dried upside down on paper towels. Plaques were first counted by 
eye using a pen to mark already counted plaques and number was recorded on side of 
corresponding well. Then plaques were confirmed via microscope with any additional 
plaques added to the number obtained by eye. Titer in PFU/mL was calculated as 
follows: 
PFU/mL = (# plaques)(dilution factor)(2) 
Agarose Gel Electrophoresis. To make desired agarose percentage, an appropriate 
amount of ultrapure agarose was dissolved in the appropriate amount of 1x TBE buffer 
in a 500 mL glass flask. Flask was weighed on balance. Flask was microwaved for 2 
minutes and left to cool until comfortable to touch. Flask was reweighed to determine 
mass lost due to evaporation; ddH2O was added to make up to original weight as well 
as 5 μL ethidium bromide (EtBr) for nucleic acid staining. The liquid agarose was 
poured into a clean gel tray with its ends sealed with tape and the appropriately sized 
combs in place. Gel was allowed to set at RT after any bubbles were popped and debris 
removed. Tape was removed before placing the gel in the Horizon 11.14 BRL 
Horizontal Gel Electrophoresis Apparatus (Life Technologies, Gibco). Apparatus was 
flooded with 1x TBE until top of the gel was completely covered. A test mixture of 5 
parts TE mM NaCl and 1 part 6x loading dye was used to ascertain well integrity. Each 





breaks in the well. Text mixture was removed by pipetting 1x TBE up and down into 
the well. Each tube of DNA to be run had 2 μL 6x loading dye added to track their 
movement through the gel. About 4-6 μL of a DNA ladder of appropriate size, usually 
1 kb, were added to the first well. About 15-25 μL of each tube of DNA were added to 
the next wells. Before running, another 10 μL EtBr was added to the 1x TBE buffer for 
better staining. Gels were run at constant voltage at appropriate voltages for the known 
or presumed lengths of the DNA fragments (≤1 kb fragments were run at 5 V/cm, 1-12 
kb were run at 4-10 V/cm, and ≥12 kb were run at 1-2 V/cm). Gel would be run for 
several hours at higher voltages or overnight at low voltages.       
Section 2: galK-DOG Double Selection Cloning Process 
Description of HSV-2 Strain R519. HSV-2 Strain R519 is a plaque-purified strain from 
HSV-2 strain 333, which was isolated from a genital lesion by W. Rawls at Baylor 
College of Medicine in Houston, Texas and strictly passaged in human cells, 
presumably to prevent attenuating or non-human-species-specific adaptive mutations 
(Westmoreland and Rapp 1976). This strain also does not produce syncytia (Wang et 
al. 2012). Strain R519 was passaged in Vero cells for all following experiments. 
Bacterial Cells. H312-1B-S1 was transformed in SW102 cells, a strain derived from 
DY380 so it has the λ prophage recombineering system. For detailed information about 
the creation of the H312-1B-S1 BAC using Cre-Lox recombination and galK-DOG 
double selection, please see Wang et al. 2012.  
Media, Antibiotics, and Plates Used for Bacterial Culture. Chloramphenicol, an 
antibiotic that inhibits protein synthesis, was used as the selector for transformants. To 





(EtOH) in a 50 mL Falcon tube; stocks were stored at -20 oC when not in use and kept 
on ice when in use. Luria-Bertani (LB) media was made by combining 10 g tryptone, 
5 g yeast extract, and 5 g NaCl in 1 L of ddH2O. LB agar (LA) was made by adding 
agar to 1.5% final concentration to the appropriate amount of LB media. LB and LA 
were autoclaved on P3 cycle to sterilize. LB was cooled to RT and stored on bench at 
RT for later use. LA was cooled to 56 oC in a 56 oC water bath before pouring. The 
appropriate amount of chloramphenicol to make a final concentration of 12.5 μg/mL 
was added to LA (LA-C) before plating 20 mL LA-C per plate. Plates were left at RT 
individually stacked for about 30-40 minutes to solidify. Plates were parafilmed and 
stored at 4 oC until later use. Plates were placed at RT for several hours before use to 
reduce condensation and increase absorption. M9 media was made by adding 6 g 
Na2HPO4, 3 g KH2PO4, 1 g NH4Cl, and 0.5 g NaCl to 1 L molecular grade water. 1x 
M63 minimal media was made by adding 2 g (NH4)2SO4, 13.6 g KH2PO4, and 0.5 mg 
FeSO4∙7H2O to 1 L molecular grade water, adding KOH to adjust pH to pH 7. After 
autoclaving on P3 cycle, sterilized M9 and M63 media were stored at RT. For M63 
minimal media plates, the following solutions were made: 1 M MgSO4∙7H2O solution 
by adding 24.67 g MgSO4∙7H2O to 100 mL molecular grade water that was 0.22 μm 
sterile-filtered before storage at RT; 0.2 mg/mL d-biotin in molecular grade water that 
was dissolved by stirring on a stir plate and then 0.22 μm sterile-filtered into 10.5 mL 
aliquots in 15 mL Falcon tubes before storage at 4 oC; 20% galactose or DOG in 
molecular grade water that was 0.22 μm sterile-filtered in aliquots stored at RT; 20% 
autoclaved glycerol in molecular grade water; and 10 mg/mL L-leucine in warm 





0.22 μm sterile-filtered into 9.5 mL aliquots in 15 mL Falcon tubes for storage at -20 
oC. To make M63 minimal media plates, 1 L 1x M63 media with 15 g agar (M63-A) 
was autoclaved on P3 and left to cool until comfortable to touch. Then 1 mL 1 M 
MgSO4∙7H2O, 10 mL galactose or DOG, 5 mL biotin, 4.5 mL leucine, and 500 μL 12.5 
μg/mL chloramphenicol was added to M63-A mixture. After pouring 20 mL per plate, 
plates were left to solidify at RT before storage at 4 oC.    
Transformation of DH5α Cells with galK Plasmid. The galK cassette was contained in 
a pBluescript SK (-) plasmid backbone that contains ampicillin resistance (Figure 3). 
The orientation of the f1 origin in the plasmid allows expression of antisense ssDNA. 
Two premade 100 μg/mL carbenicillin plates were thawed at RT. Two empty 
microcentrifuge tubes were chilled on ice. Control pUC19 plasmid and 78 ng/μL galK 
plasmid stock were thawed on ice with intermittent tapping to ensure dissolving. The 
galK plasmid stock was diluted to 1 ng/μL in a chilled microcentrifuge tube. Competent 
DH5α cells were thawed on ice; 50 μL were pipetted into each of the chilled empty 
microcentrifuge tubes. Then 0.5 ng of control pUC19 and 1 ng of galK plasmid were 
added to their respective tubes. Tubes were gently tapped to mix and incubated on ice 
for 30 minutes. Tubes were heat shocked at 37 oC for exactly 20 seconds and 
immediately returned to ice. After tubes were chilled for 2 minutes on ice, 0.95 mL LB 
media were added to the tubes. Tubes were incubated at 37 oC, 225 rpm for 1 hour for 
recovery. After recovery, 100 μL was plated on one half of each plate and 10 μL was 
plated on the other half of each plate. After spreading the cells, plates were left at RT 
to allow culture absorption. After culture was fully absorbed, plates were incubated 





galK Plasmid Purification. Selected transformant colonies were picked with a sterile 
toothpick. Inoculated toothpicks were added to 5 mL LB with 0.1 mg/mL ampicillin. 
Tubes were incubated at 37 oC, 225 rpm overnight. The galK plasmid was isolated 
using the QIAprep Spin Miniprep kit (QIAGEN). Bacterial cells were harvested at 8000 
rpm at RT for 3 minutes. Supernatant was decanted and pellet resuspended in 250 μL 
Buffer P1. Resuspended cells were transferred to new microcentrifuge tubes before 
adding 250 μL Buffer P2. Tubes were mixed by inverting 4-6 times. Then 350 μL 
Buffer N3 was added to the tubes, which were immediately inverted 4-6 times. Tubes 
were centrifuged at 13000 rpm at RT for 10 minutes. Supernatants were transferred to 
new tubes and respun at the same conditions. Supernatants were added to QIAprep spin 
columns and centrifuged at 13000 rpms at RT for 60 seconds. Flow-through in the 
collection tubes was discarded. QIAprep spin columns were washed with 0.5 mL 
Buffer PB and centrifuged at 13000 rpm at RT for 60 seconds. Flow-through in the 
collection tubes was discarded. QIAprep columns were washed with 0.75 mL Buffer 
PE and centrifuged at 13000 rpm at RT for 60 seconds. Flow-through was discarded 
before additionally centrifuging the tubes at 13000 rpm at RT for 1 minute. QIAprep 
columns were placed in a new microcentrifuge tube. Plasmid DNA was eluted in 200 
μL water by adding water to QIAprep spin columns, incubating at RT for 1 minute, and 
centrifuging at 13000 rpm at RT for 1 minute. Plasmid concentration was determined 
by nanodrop. Tubes were stored at -20 oC.       
Restriction Enzyme Digestion of Purified galK Plasmid. To confirm the galK plasmid 
isolated had the same restriction enzyme digestion pattern as the original stock used in 





position 1252, and HindIII, which would cut at position 4161, to create a 1267 bp 
fragment and a 2909 bp fragment. Tubes were made with 150 ng plasmid; 15.35 μL of 
a master mix consisting of 1 μL 10 U/μL NotI, 1 μL 20000 U/mL HindIII, and 2 μL 
10x Buffer 3 (NEB) per tube; and water up to a total of 20 μL. Tubes were incubated 
at 37 oC for 1 hour. DNA along with a 1 kb ladder was run on a 1% agarose gel at 90 
V for 2 hours. Pictures of gel were taken in closed UV box.   
Transformation of DH10B strain SW102 Cells with H312-1B-S1 BAC. Cells were 
thawed on ice and kept on ice at all times. Once thawed, 25 μL of cells were transferred 
to a chilled microcentrifuge tube on ice and then mixed with 1-5 μg H312-1B-S1. 
Mixture was pipetted into the slot of a 0.1 cm chilled cuvette, taking care to not create 
bubbles. The cuvette was electroporated at 25 μF, 1.75 kV, and 200 Ω with a shock 
value of at least 4.5. The cuvette was immediately removed after the machine beeped. 
One mL of recovery medium was pipetted up and down into the slot to resuspend the 
cells. Recovery medium with cells was transferred to a 10 mL round bottom tube and 
incubated at 37 oC at 200-250 rpm for 1 hour. A LA-C plate was warmed at RT before 
100 μL of culture was plated on one half of the LA-C plate. The remaining 900 μL was 
centrifuged at 13000 rpm for 1 minute to form a cell pellet. About 800-850 μL of 
supernatant was aspirated off and the pellet was resuspended in the remaining 50-100 
μL media before being plated on the other half. Plate was incubated upside down at 37 
oC in a plastic bag to avoid drying out after culture was absorbed by agar.  
BAC Purification. Any missing materials for the media were ordered as follows: d-
biotin (Supelco) and DOG (MP) stored at 4 oC; L-leucine, sodium phosphate dibasic 





Aldrich) stored at RT; restriction endonuclease DpnI (NEB) stored in restriction 
enzyme ice block at -20 oC; and Expand High Fidelity PCR kit (Roche) stored at -20 
oC.  All BACs were purified using Macherey-Nagel’s NucleoBond BAC 100 kit and 
protocol for low-copy plasmid purification with minor changes. SW102 cells 
transformed with the appropriate BACs were grown up in 100 mL cultures with 12.5 
μg/mL chloramphenicol at 30 oC, 225 rpm overnight. Cells were pelleted at 6000g at 4 
oC for 15 minutes and then resuspended in 24 mL of Buffer S1 with RNase A. After 
adding 24 mL Buffer S2 while swirling the tubes, they were gently inverted 6-8 times 
to mix and left at RT for 2-5 minutes. Then 24 mL of chilled Buffer S3 were added to 
tubes while swirling them, which were immediately inverted 6-8 times to mix and 
incubated on ice for 5 minutes. While incubating, NucleoBond BAC 100 columns were 
equilibrated with 6 mL of Buffer N2. Columns were emptied by gravity flow with flow-
through being collected into a tray. Folded filters were placed in funnels placed on top 
of each column and wet with a few drops of Buffer N2. Contents of the now lysed 
cultures were loaded into the wet filters and allowed to flow through the columns by 
gravity. Filters were gently squeezed to remove more liquid. Columns were washed 
twice with 18 mL of Buffer N3. Buffer N5 was preheated to 50 oC to increase BAC 
yield. BACs were eluted from the columns with 15 mL warmed Buffer N5 into 
Oakridge tubes. BACs were precipitated by adding 11 mL RT isopropanol to the tubes 
and centrifuging at 15000g at 4 oC for 30 minutes. After supernatants were discarded 
in 50 mL Falcons in case the pellets were lost, 1 mL RT freshly prepared 70% ethanol 
was added to the pellets. Tubes were vortexed briefly before centrifugation at 15000g 





microcentrifuge tubes in case pellets were lost. Pellets were allowed to dry for 10-20 
minutes before resuspending them in the desired amount of ddH2O. Pellets were 
checked every 5 minutes while drying to ensure they did not over-dry. Pellets were 
resuspended in 100 μL water by swirling tube as pipetting could shear the BACs. Tubes 
were put in 65 oC water bath for 1 hour to facilitate dissolving. Water containing 
resuspended pellets was transferred to empty microcentrifuge tubes. Another 100 μL 
of water was added to Oakridge tube to wash and dissolve any remaining BAC DNA 
and transferred to the corresponding microcentrifuge tubes. BAC DNA concentration 
was determined by nanodrop before storage at 4 oC.        
galK-DOG Double Selection. As this procedure is quite long, it has been broken down 
into subsections. This entire process has been adapted from the procedure detailed in 
Warming et al. 2005 with minor changes.  
 Confirmation of R519-Specific Mutations. Any R519-specific mutations in and 
around UL30, UL31, and UL34 were found via alignments of multiple HSV-2 strains to 
reference HSV-2 strain HG52 that were compiled by Dr. Susanna Lamers of 
Bioinfoexperts, LLC and Dr. Ruchi Newman formerly of the Broad Institute and now 
of the Ragon Institute of MGH, MIT, and Harvard. Mutations were confirmed by 
analysis of a deep sequencing file of R519 to ensure mutations were genuine (Table 1).  
PCR of galK cassette. Primers (IDT) were designed as follows: a 50 bp 
homologous region to flanking areas of UL30, UL31, and UL34 attached to 20-25 bp of 
galK sequence to make 70-75mers (Table 2). Lyophilized primers were dissolved in 
the appropriate amount of sterile molecular grade water to make 100 μM stock 





make a 1:20 dilution for 5 μM working concentration solutions by adding 1 μL stock 
solution to 19 μL sterile molecular grade water. galK plasmids were diluted to 10 ng/μL 
in molecular grade water. PCR was performed on the galK cassette with the above 
primers. Each PCR tube was made as follows: 1 μL 10 ng/μL galK plasmid, 3 μL 5 μM 
forward primer, 3 μL 5 μM reverse primer, 4.5 μL 10x EHF buffer, and 33.5 μL 
molecular grade water. A master mix of dNTPs and DNA polymerase was made to 
have the following volumes of each reagent per tube: 0.5 μL 10x EHF buffer, 1 mM 
dNTP, 0.35 μL EHF polymerase, and 3.15 μL molecular grade water. Mixtures were 
run under the following conditions: 96 oC for 5 minutes; 30 cycles of 94 oC for 15 
seconds, 60 oC for 30 seconds, and 72 oC for 1 min; 72 oC for 7 minutes; and 4 oC 
indefinitely. Each tube had 5 μL master mix added when the first 30 seconds at 60 oC 
was hit. After PCR run was done, 2 μL of 6x loading dye was added to 6 μL of each 
PCR reaction. All PCR reactions along with a 1 kb ladder were run on premade 1% 
agarose gel at 90 V for 2 hours. Remaining PCR reactions were stored at -20 oC. This 
PCR reaction was done twice and so corresponding PCR products were pooled together 
after confirmation on gel that all PCR products from both runs were the appropriate 
length of 1.3 kilobases (kb) without unknown bands or contamination.      
DpnI Clean-Up of galk Cassette PCR Products. Clean-up was performed by 
adding 2 μL DpnI per 50 μL PCR products, which only cuts methylated DNA and thus 
will degrade any template plasmid DNA left. Mixtures were incubated at 37 oC for 1 
hour before being run on a premade 0.8% agarose gel at 25 V overnight.  
Gel Purification of Dpn1-Cleaned-Up PCR Products. Gel extraction of these 





(QIAGEN). A scalpel was used to cut out the UV-illuminated bands on the gel. Gel 
fragments were placed into microcentrifuge tubes and weighed. Three volumes of 
Buffer QG were added to 1 volume of gel; for example, one gel fragment weighed 270 
mg, so 3 x 270 = 810 μL Buffer QG was added to it. If fragments weighed more than 
400 g, multiple spin columns were used. Tubes were incubated at 50 oC for 10 minutes 
until the gel fragments were dissolved. The colors of the tube were confirmed to be 
yellow. One gel volume of isopropanol was added to each tube. After mixing, the 
solutions were pipetted into QIAquick spin columns placed in collection tubes and 
centrifuged at 13000 rpm at RT for 1 minute. Flow-through was discarded and 0.5 mL 
Buffer QG was added to each QIAquick spin column to remove all agarose. QIAquick 
spin columns were centrifuged at 13000 rpm at RT for 1 minute again. Flow-through 
was discarded before the spin columns were washed with 0.75 mL Buffer PE. Columns 
incubated at RT for 5 minutes with Buffer PE before being centrifuged at 13000 rpm 
at RT for 1 minute. Flow-through was discarded before an additional spin at the same 
conditions was performed to remove all ethanol. Spin columns were placed into empty 
microcentrifuge tube. DNA was eluted into 30 μL molecular grade water. Spin columns 
were incubated at RT for 1 minute after water was added. After centrifugation at 13000 
rpm at RT for 1 minute, 2 μL of purified DNA along with a 1 kb ladder was run on a 
premade 0.8% agarose gel at 90 V for 90 minutes. Approximate DNA concentration 
was determined by intensity and size of the bands compared to the 60 ng of the 1000 
kb band in the 1 kb ladder. Eluted DNA was stored at -20 oC.  
Transformation of H312-1B-S1 with galK Cassette. Cleaned PCR products 





oC until use. A vial of SW102 bacteria containing the H312-1B-S1 BAC was placed on 
dry ice. Three 5 mL aliquots of LB with 12.5 μg/mL chloramphenicol in 50 mL Falcon 
tubes were inoculated with SW102 glycerol stock by scraping off some frozen stock 
with a loop and swirling it in the LB media. Glycerol stock was immediately returned 
to -80 oC after use. Tubes were loosely capped and incubated at 30 oC, 225 rpm 
overnight. Ultracentrifuge was set to 1 oC with the appropriate JA-20 rotor attached. 
Two ice buckets were prepared with one being used to chill ddH2O and 0.1 cm cuvettes 
and the other being used as an ice-water slurry for making competent cells. M63-
galactose plates were left at RT to warm up. A 25 mL LB with 12.5 μg/mL 
chloramphenicol was inoculated with 0.5 mL of the cloudiest overnight culture. Culture 
was shaken in a 30 oC water bath at 120 rpm for 3-4 hours until OD of culture was 
between 0.55-0.6. Then 10 mL of this culture was transferred to a 50 mL Falcon tube, 
which was then heat shocked for 15 minutes in a 42 oC water bath to induce 
recombineering activity. Another 10 mL aliquot of culture was left at 30 oC as 
uninduced negative control. Both cultures were cooled in the ice-water slurry, 
transferred to Oakridge tubes, and centrifuged at 8000 rpm at 1 oC for 5 minutes. The 
following process was repeated twice: supernatants were decanted, pellets resuspended 
in 1 mL ice-cold ddH2O by swirling the tubes in the ice-water slurry; once resuspended, 
9 mL ice-cold ddH2O were added to the tubes before centrifugation at 8000 rpm at 1 
oC for 5 minutes. Supernatants were decanted and tubes inverted on paper towels to 
soak up excess supernatant. Pellets were kept on ice and resuspended in 80 μL of 
ddH2O. Microcentrifuge tubes for electroporation were made as follows: 50 μL either 





PCR products. These mixtures were transferred to chilled 0.1 cuvettes which were 
electroporated at 25 μF, 200 Ω, 1.75 kV for a duration of at least 4.8. Cuvettes were 
immediately removed from electroporation machine and 1 mL LB media was pipetted 
into their slots to resuspend the transformed cells. Transformed cells were transferred 
to new microcentrifuge tubes and were recovered for 1 hour in a shaking 30 oC water 
bath. Cells were pelleted at 13000 rpm at RT for 30 seconds. After supernatants were 
decanted, pellets were twice resuspended in 1 mL 1x M9 media and re-centrifuged 
again at 13000 rpm at RT for 30 seconds. Supernatants were decanted and pellets 
resuspended in 1 mL 1x M9 media for plating on pre-warmed M63-Galactose plates. 
For uninduced controls, 100 μL of cells were plated on whole M63-Galactose plates. 
For induced cells, 10 μL were plated on one half of plates and 100 μL on the other half 
of plates. The remaining volumes of the transformed cultures were plated on separate 
whole M63-Galactose plates. All plates were incubated inverted and in a plastic bag at 
30 oC for 3 days. Colonies were chosen with a loop and restreaked on new M63-
Galactose plates every 3 days for 3 rounds of colony purification. All previous round 
plates were parafilmed and kept at 4 oC once the next round began.              
Section 3: HSV-2 Neutralization Assay by Monoclonal gD and gB Antibodies 
Antibodies. gD and gB antibody hybridomas were grown up and resultant purified gD 
and gB antibodies were supplied by Lawrence Lance. Four antibodies to gD – DL11, 
1D3, MC5, and MC2 – and one antibody to gB – C226 – were used in this experiment. 
Antibodies were aliquoted in 1-1.5 mL per microcentrifuge tube. Aliquots for 





at -20 oC. These antibodies’ epitopes and other characteristics have been previously 
described (Bender et al. 2007; Lazear et al. 2012).      
Neutralization Assay. Vero cells were seeded in 6-well plates at 8 x 105 cells per 2.5 
mL complete DMEM per well. Plates were incubated at 37 oC, 5% CO2 overnight. 
Antibodies were diluted as follows: 100 μL of 4 mg/mL MC2 and 1D3 were added to 
100 μL 2x PBS to make 200 μL 2 mg/mL solutions. Then 100 μL of 2 mg/mL MC2, 
1D3, DL11, and C226 were added to 100 μL sterile water to make 200 μL 1 mg/mL 
solutions. For controls, premade 1:10 IVIG (1%, 10 mg/mL IVIG) and 1x PBS made 
by diluting 100 μL 2x PBS in 100 μL sterile water were used. Antibodies and controls 
were diluted in 24-well plates by using a multichannel pipet to add the appropriate 
volume of PBS to all columns. For the experiment shown in Figure 6, 267.84 μL 1x 
PBS was added to the first column for MC2, DL11, 1D3, and 1x PBS to start a 1:2 
dilution series with a 1:250 dilution as the first dilution. For C226 and 1:10 IVIG, 243 
μL 1x PBS was added to the first column to start a 1:2 dilution series with a 1:20 
dilution as the first dilution. All other columns were filled with 135 μL 1x PBS. Then 
2.16 μL of MC2, DL11, 1D3, and 1x PBS were added to their first column wells and 
serially diluted by pipetting 135 μL from the previous well to the next well after mixing 
by pipetting up and down. After mixing the last well’s dilution, 135 μL were discarded. 
This same process was repeated for C226 and 1:10 IVIG with 27 μL instead of 2.16 μL 
being added to the first well. HSV-2 R519 virus with a titer of 3.29 x 105 pfu/mL was 
thawed on ice. It was then diluted in cold complete DMEM so as to produce around 
120 plaques per 135 μL per well. For this experiment, a total of 4.68 x 104 pfu were 





to 8.89 x 102 pfu/mL. Therefore, 19.6 μL of 3.29 x 105 pfu/mL viral stock were added 
to 7.3 mL complete DMEM. Then 135 μL of diluted virus was added to each well of 
antibody dilution made in the 24-well plates. The virus-Ab mixtures were incubated at 
RT for 1 hour with tilting every 20 minutes. Complete DMEM was removed from 6-
well Vero plates via vacuum pipeting and replaced with 200 μL pre-warmed complete 
DMEM with Repipetter. All virus-Ab mixtures were transferred to Vero cells and 
incubated at 37 oC, 5% CO2 for 1 hour with tilting every 15 minutes. Inoculum was 
removed via vacuum pipetting and replaced with 2.5 mL overlay medium per well. 
This overlay medium is identical to that used in the plaque assay described above. 
Plates were incubated at 37 oC, 5% CO2 for 2 days. Overlay media was removed from 
wells via vacuum pipetting. Wells were stained with 1 mL plaque staining solution and 
incubated for 1 hour at RT. Plates were washed in water by submerging and lifting until 
water ran clear. Plates were dried on paper towels before plaque counting as described 
in the plaque assay protocol above. The IC50 values of antibodies and 1:10 IVIG control 
were calculated in Prism.  
Calculation of IC50 in Prism Software. After opening the Prism software, the 
option “Enter and plot a single Y-value for each point” was selected. Dilution values 
were entered in the X column as x-values and plaque numbers were entered in the Y 
column as y-values. Next, the “Analyze” option was chosen to bring up a menu screen; 
the option “Transform” was chosen from this menu screen to drop down a small options 
list. After the option “Transform X values using” was chosen, the option “X = log(X)” 
was chosen and confirmed by clicking “Okay.” After the “Analyze” option was 





clicking “Okay.” After confirmation, the option “Standard Curves to interpolate” was 
selected and then the “sigmoidal, 4PL, X is log(concentration)” option was selected. 
The “Constrain” option was selected to set top and bottom constraints. Top constraint 
was set to the average number of plaques – in this experiment, 61.8 – found in the 1x 
PBS negative control. Bottom constraint was always set to 0 plaques. The constraints 
were confirmed by clicking “Okay.” The resulting graph was generated with a list of 
statistics such as IC50 values, log(IC50) values, degrees of freedom, R square values, 
and absolute sum of squares values. IC50 values given by Prism are unitless since 
dilution was used as the independent variable. To find IC50 values in concentrations, 
the original concentration of the mAbs – 1 mg/mL – were divided by the IC50 





Chapter 3: Results 
First Step of galk-DOG Double Selection  
PCR Products. PCR was performed on the galK gene with primers that had 50 bp 
homology to the flanking regions of UL30, UL31, and UL34 to create the corresponding 
galK cassettes (Figure 5). When products were run on a gel, all bands were 1.3 kbp, 
which corresponded to the expected 1331 bp length of galK (Figure 5A). No strong 
bands at other lengths were seen, but leftover template DNA probably was still present. 
PCR products were then cleaned with DpnI, which cleaves methylated DNA, to remove 
any traces of pGalK template DNA. These cleaned products were again run on a gel, 
showing the same length of 1.3 kbp as before with no bands at 4.2 kbp, which is the 
size of pGalK. These bands were gel purified and run again on a gel to assess 
approximate concentration (Figure 5B). Since the 1 kb band is 60 ng, UL30 and UL31 
are about 130 ng/μL and UL34 is about 65 ng/μL.  
Transformation of H312-1B-S1 with galK Cassette. All plates with transformants grew 
on the M63-Galactose plates, indicating initial success that the corresponding galK 
cassettes replaced UL30, UL31, and UL34 in the H312-1B-S1 BACs. After three rounds 
of colony purification, no colony “dropped out,” meaning that it suddenly didn’t grow 
in the next round, which would indicate that it was a hitchhiker WT BAC-containing 
colony. No confirmation other than the fact that they grew on M63-Galactose media, 
indicating that they were able to break down galactose presumably due to expression 
of galK, to confirm correct galK cassette insertion was done for this thesis, so please 





Neutralization Assay of Monoclonal gD and gB Antibodies   
IC50 Values of gD and gB mAbs. A single neutralization assay experiment determined 
the IC50s for three gD mAbs – MC2, DL11, and 1D3 – and one gB mAb C226 compared 
to a 1:10 dilution of IVIG and a PBS-only negative control (Figure 6).  These three gD 
antibodies’ epitopes and structure have been previously described by Lazear and 
colleagues (Lazear et al. 2012). MC2 is a HSV-2-specific antibody that recognizes a 
discontinuous epitope (aa 246) on the fusion activation face of gD (Lazear et al. 2012). 
IC50 values were generated based on the concentration of antibody needed to neutralize 
50% of HSV-1 strain KOS plaques and HSV-2 strain 333 plaques on Vero cells 2 DPI. 
MC2 required over 25 μg/mL to neutralize HSV-1 compared to 0.781 μg/mL for HSV-
2 (Lazear et al. 2012). DL11, 1D3, and C226 are all common-type antibodies, meaning 
they recognize both gD1 and gD2 (Bender et al. 2007; Lazear et al. 2012). DL11 
recognizes a discontinuous epitope (aa 132. 140) on the receptor binding face of gD 
(Lazear et al. 2012). DL11 had low IC50s for both strains, needing only 0.004 ug/mL to 
neutralize HSV-1 and 0.312 μg/mL to neutralize 50% of HSV-2 strain 333 (Lazear et 
al. 2012). 1D3 recognizes a continuous epitope (aa 10-20) on gD (Lazear et al. 2012). 
1D3 has slightly better neutralizing activity on HSV-1 with an IC50 of 0.390 μg/mL for 
HSV-1 strain KOS and 6.2 μg/mL for HSV-2 strain 333 (Lazear et al. 2012). C226 
recognizes a pseudocontinuous epitope (aa 234-472) in the FR2 domain of gB to block 
viral fusion (Bender et al. 2007).  
All three gD mABs had lower IC50s than that of IVIG, indicating that they were 
more effective than 1% IVIG at inhibiting HSV-2 infection (Table 3). MC2 had a IC50 





mg/mL is divided by these values, the IC50 concentrations are as follows: 2 μg/mL for 
MC2, 0.7 μg/mL for DL11, and 0.9 μg/mL for 1D3. The 1:10 IVIG dilution had an IC50 
of 105.7, so when 1 mg/mL is divided by this value, an IC50 concentration of 9 μg/mL 
is given. Therefore, MC2 was about 2.5-fold less effective at HSV-2 R519 
neutralization compared to its literature value of 0.781 μg/mL for HSV-2 333. DL11 
was also about 2-fold less effective at R519 HSV-2 neutralization compared to its 
literature value of 0.312 μg/mL for HSV-2 333. On the other hand, 1D3 was about 7-
fold more effective at neutralizing HSV-2 R519 since its literature value for HSV-2 
333 neutralization was 6.2 μg/mL. C226 had a very low IC50 of 46.9, giving its IC50 
concentration as 20 μg/mL. Bender and colleagues found C226’s IC50 to be 1.2 μg/mL, 
showing that this antibody was about 17-fold less effective at neutralizing virus than 
its literature IC50 concentration (Bender et al. 2007). The PBS-only control did not 
show any neutralization activity, indicated by the relatively straight best-fit line made 
by its points versus the sigmoidal lines made by the mAbs and IVIG.    







Chapter 4: Discussion 
Section 1: Discussion of Results 
Viability of galK clones of H312-1B-S1. A high number of transformant colonies for 
each CPBD gene (named galK-UL30, galK-UL31, and galK-UL34) were colony purified 
at least three times to minimize the probability of mistakenly growing up hitchhiker 
colonies containing the wild-type H312-1B-S1 BAC. The colonies for galK-UL31 and 
galK-UL34 seemed consistently smaller than the colonies for galK-UL30, so colonies 
of both small and large colony phenotypes were purified. Due to no colony “dropping 
out” during the three rounds of purification, it is reasonable to assume that all isolated 
transformant colonies of each CPBD gene were successfully transformed with their 
respective galK cassette. However, it is possible that the galK gene could have been 
inserted non-homologously into a different site in the BAC HSV-2 genome than 
expected, resulting in E. coli containing different BAC clones that grow at different 
rates. 
Monoclonal gD and gB Antibody IC50 values. The neutralization assay shows that the 
gD antibodies MC2, DL11, and 1D3 had IC50s five to ten times that of IVIG, whose 
IC50 of 105.7 or 9 µg/mL is around what is normally expected of IVIG. The IC50s were 
2 μg/mL for MC2, 0.7 μg/mL for DL11, and 0.9 μg/mL for 1D3, showing that all these 
gD antibodies were highly effective at neutralizing HSV-2 strain R519. The gB 
antibody C226 had a low IC50 of 46.9, meaning its IC50 was 20 μg/mL, which is in stark 
contrast to its published IC50 of 1.2 μg/mL (Bender et al. 2007). C226 was found to be 





 Though it may seem that IVIG should be the best at neutralizing HSV-2 as it is 
pooled IgG from thousands of human donors, there could be several reasons as to why 
IVIG was less effective than all by one mAb. Since IVIG contains antibodies against 
multiple pathogens, the concentration of HSV-2-specific antibodies might be relatively 
low. Also, the affinity of these HSV-2-specific antibodies might be low as well, so they 
cannot neutralize HSV-2 due to poor binding to epitopes. Epitope competition between 
antibodies may also play a role in low neutralizing activity; if multiple antibodies bind 
the same epitope, fierce competition for these common epitopes could lead to 
obscuration of more cryptic epitopes of antibodies that might be more potently 
neutralizing. Another scenario may be IVIG just contains non-neutralizing antibodies 
which cannot neutralize virions at all.      
The large discrepancy between C226’s IC50 value in the literature and this 
neutralization assay needs to be resolved. Repeating this neutralization assay would 
confirm if these data were incorrect especially since only one neutralization experiment 
was performed due to time constraints. Other factors may contribute to this 
inconsistency such as the age of the antibody, how it was stored, and how many freeze-
thaws it went. As it stands, Bender et al.’s reported literature IC50 value is quite low, 
which may be due to the use of fresh, newly isolated antibody that had not undergone 
freeze-thaws, which causes antibodies to lose activity (Bender et al. 2007). The 
antibodies used in this experiment were sent from another lab that might have stored 
them differently than Bender’s lab. Aliquots were stored at 4 oC for over a month before 





despite the lack of freeze-thawing. In addition, the IC50 values of the gD mAbs should 
be reconfirmed with more repetitions of neutralization assays. 
The differences between the literature and experimental IC50s also could be due 
to differences in the epitopes recognized by these antibodies between HSV-2 strain 333 
and R519. Even though R519 is a plaque-purified strain of 333 so the nucleotide and 
amino acid differences between the two strains should be minimal, it is possible that 
some mutations had been introduced into the R519 genome during plaque purification 
that have changed the epitopes on gD and gB. These changes to the epitopes could have 
decreased or increased these antibodies’ affinity for their epitopes, which would 
explain why some antibodies such as C226, DL11, and MC2 were less effective while 
other antibodies such as 1D3 were more effective at virus neutralization.   
Section 2: Future Directions 
Cloning. Purified BACs for all transformants need to be digested to see if they show 
the correct restriction enzyme digestion pattern on an agarose gel for H312-1B-S1. 
Primers were already made to PCR the UL30, UL31, and UL34 regions to see if the galK 
cassette was inserted with the expected lengths for non-insertion (3856 and 745 bp for 
UL30, 1083 bp for UL31, and 1077 bp for UL34) and galK insertion calculated. PCR 
will be run on the colony purified bacteria’s BACs and products run on gels to see if 
the correct galK-BAC lengths of 1464 bp for UL30, 1497 bp for UL31, and 1577 bp for 
UL34 were seen. If so, it would be reasonable to assume that these colonies do contain 
the BACs with galK instead of spontaneous gain of the ability to grow on M9 media. 
However, it is possible that the galK gene might have undergone non-homologous 





One way to further confirm the correct insertion of galK in the desired loci is to 
sequence the UL30, UL31, and UL34 regions from purified BACs isolated from these 
colonies. To confirm that H312-1B-S1 has not undergone major alterations during 
insertion of the galK cassette and subsequent amplification in bacteria, restriction 
enzyme digestion of the BAC after galK cassette insertion should be done.  
Because only the first step of galK insertion was completed for this thesis, the 
second step of replacing the galK gene with the CPBD UL30, UL31, and UL34 genes 
must be completed next. These three genes would be inserted into their proper place 
and orientation into their respective BACs via the same transformation protocol 
described in the Methods section, thereby creating three BACs each containing a single 
CPBD gene – H312-1B-S1-UL30, H312-1B-S1-UL31, and H312-1B-S1-UL34. 
Transformed E. coli cells will be plated on media containing DOG to select for H312-
1B-S1-UL30, H312-1B-S1-UL31, and H312-1B-S1-UL34 transformants as cells still 
containing BACs with galK insertions will die since galK catalyzes DOG into a toxic 
intermediate. Considering this second selection step is relatively leakier than the first 
step, more than three rounds of colony purification on DOG-containing media should 
be done to minimize hitchhiker galK-BAC-containing colonies.  
Purified colonies containing H312-1B-S1-UL30, H312-1B-S1-UL31, and 
H312-1B-S1-UL34 will be grown up in LB media containing chloramphenicol to 
maintain the BACs, as described above. Considering that these BACs are extremely 
low copy number compared to plasmids due to their large size, much troubleshooting 
has determined that at least 100 mL of culture needs to be used during the BAC 





multiple purified colonies will be grown up in sizes of at least 100 mL and undergo 
BAC extraction using the Macherey-Nagel BAC 100 kit to confirm these colonies 
indeed have H312-1B-S1-UL30, H312-1B-S1-UL31, or H312-1B-S1-UL34.  
Purified H312-1B-S1-UL30, H312-1B-S1-UL31, and H312-1B-S1-UL34 will 
be nucleofected into Vero cells using Lonza’s Nucleofector kit and Amaxa protocol for 
Vero cells. Transfection of BACs by conventional methods of lipofectamine or Trans-
It has low efficiency due to their much larger size than plasmids. Nucleofected Vero 
cells will be added to T175 flasks with 25 mL complete DMEM and incubated at 37 
oC 
until cytopathic effect (CPE) is 90-100% before the resultant viruses are harvested. 
Considering that these resultant viruses might show some attenuation in cell culture, 
the amount of incubation time needed until 100% CPE may vary between the H312-
1B-S1-UL30, H312-1B-S1-UL31, or H312-1B-S1-UL34 nucleofected Vero cell flasks. 
Cell-free virus will be made from harvested infected Vero cells and titered by plaque 
assay to determine viable virus content in PFU/mL. When not in use, cell-free virus 
will be stored in cryovials at -80 oC to preserve viability. The viruses will be 
characterized by restriction enzyme analysis to ensure no genome rearrangements 
occurred during their rescue from bacteria and to confirm the codon deoptimized 
sequences are stable.    
The H312-1B-S1-UL30, H312-1B-S1-UL31, or H312-1B-S1-UL34 viruses will 
first be characterized in cell culture before testing them in mice. Growth curves will be 
done for each virus to ensure they grow to reasonably comparable titers to wild-type 
virus. If these viruses are too attenuated to grow to high enough titers, replacement of 





should be done to see if it rescues the low titer phenotype in vitro. If they grow to 
comparable titers to wild-type in vitro, they show that they have potential as vaccine 
candidates from a manufacturing standpoint and should be evaluated for safety and 
efficacy in mice, respectively.  
CPBD H312-1B-S1-UL30, H312-1B-S1-UL31, and H312-1B-S1-UL34 Vaccine 
Candidate Animal Studies. Evaluating these viruses as vaccine candidates first requires 
confirming their safety in mice. BL/6 female healthy 6-week-old naïve mice will be 
inoculated intravaginally with a range of doses to determine the mouse lethal dose 50 
(MLD50), or the number of virions required to kill off 50% of infected mice, of the 
viruses. The dosage scale should be calculated based on known dosages of wild-type 
virus that mice can and cannot survive. The dosage scale should incorporate very low 
dosages that mice theoretically should be able to survive, so any deaths or euthanasia 
due to weight loss or hind limb paralysis in these low dosage groups would immediately 
indicate if these viruses have very low LD50s and thus are unsafe. Conversely, the 
dosage scale should also include very high dosages that mice theoretically should not 
be able to survive to make sure the LD50, which should be higher for H312-1B-S1-
UL30, H312-1B-S1-UL31, and H312-1B-S1-UL34 as they contain CPBD genes, is not 
missed. Obviously, this safety study should be controlled with mice receiving the same 
dosages of parent wild-type strain R519 as a positive control and receiving only the 
vaccine formulation without virus as a negative control to check for toxicity of non-
viral materials.  
Mice will be monitored for primary infection symptoms such as genital lesions, 





lesions should be assessed to see if there is any noticeable difference compared to wild-
type infected mice. Bleeds should be done to look at antibody titers via neutralization 
assays and T cell responses via flow cytometry.  
The major concern would be to determine if the vaccine viruses were able to 
establish latency in the DRGs, which can be assessed in three major ways. First, 
periodical vaginal swabbing over at least several weeks and preferably longer to better 
mimic viral shedding in humans should be done for plaque assays to assess frequency 
and amount of viral shedding, which would suggest that the vaccine virus established 
latency in the DRGs. Further analysis of vaginal mucosal immunity should be done via 
neutralization assays using vaginal swabs to see how much antibody is traversing the 
mucosal layer of the vagina. However, since mice do not shed for more than 7-10 days 
after vaccination, these swabs would only inform about acute vaginal shedding; chronic 
vaginal shedding over long durations would have to be assessed in guinea pigs. Second, 
stimulation of HSV-2 reactivation in vaccinated mice would show if recurrent lesions 
formed, which could only happen if latency was established in the DRGs. Since UV 
light has been used to reactivate latent ocular herpes, UV light should be used to try to 
stimulate reactivation of latent genital herpes. If reactivation is not achieved in mice, 
this information will be gathered from vaccinated guinea pigs, which do have 
spontaneous reactivation. Third, all mice should have their DRGs harvested for 
quantitative PCR (qPCR) to determine how many HSV-2 genome copies, if any, are in 
the DRGs. Ideally, these vaccine candidates should not establish latency in the DRGs 
and consequently have little to no sustained viral shedding in the genital mucosa while 





CoPs to protect from infection for a prophylactic vaccine or from disease for a 
therapeutic vaccine.    
If any mice died during the safety study, especially at the lower dosages, their 
antibody response in particular should be compared to mice who survived to see if there 
is any difference between type and number of antibodies generated. This scenario may 
indicate that the viruses are not attenuated enough to be safe, which means that the viral 
BACs should be reconstructed with more CPBD genes or other attenuation methods 
like missense mutations or deletions. For example, any combination of the three CBPD 
genes – UL30/UL31, UL31/UL34, UL30/UL34, or UL30/UL31/UL34 – could be inserted 
together into the BAC to further attenuate the virus. On the other hand, if very little 
antibody response was generated at the higher dosages, these viruses may be too 
attenuated to elicit an immune response that would protect them from infection or 
disease. These BACs would then have to be reconstructed with only partially CPBD 
UL30, UL31, and UL34 to partially rescue the attenuated phenotype to boost viral 
replication to induce a more robust immune response. 
After safety of these vaccine candidates have been confirmed in mice, 
vaccination with viral challenge studies should be conducted to analyze their ability to 
either prevent infection or protect from disease, hopefully allowing the deduction of 
the CoP for HSV-2. Again, BL/6 female healthy 6-week-old naïve mice will be 
vaccinated intravaginally with different doses chosen based on data from the safety 
studies. Any primary infection symptoms caused by the vaccine viruses should be 





Then these mice should be challenged with different doses of wild-type HSV-
2 to determine the extent of protection they provide. Challenge doses should be chosen 
based on the MLD50 of the wild-type virus; a low dose that the vaccine virus should be 
able to protect against, a medium dose that mimics the average challenge viral dose 
that humans encounter during natural infection, and a large dose that theoretically 
should overwhelm the immune response should be included. Multiple challenges over 
several weeks to months and even longer to mimic the multiple exposures to HSV-2 
humans have during their lifetimes should be done to see if the vaccine candidates 
established long-lasting immunity in the hosts. During these long-scale challenges, 
bleeds and vaginal swabs of the mice should be done to look at antibody titer as well 
as T cell changes over time to determine what overall and mucosal immune responses 
are necessary to protect from infection or disease.   
Lack of protection at the low and medium doses would indicate that the vaccine 
is not viable whereas protection at the high dose indicates that the vaccine induces a 
very robust immune response that probably exceeds that induced by natural infection, 
so it should be a good vaccine candidate for humans. The severity, duration, and 
number of lesions in addition to mouse-specific HSV-2 symptoms such as hind limb 
paralysis, lethargy, and ruffled fur should be monitored during the challenges. Vaginal 
swabs should be done to determine frequency and amount of viral shedding, 
neutralization assays using vaginal swabs should be done to look at musical antibody 
titers, and DRGs from these mice also should be harvested to determine if the challenge 
virus established latency. If these vaccine candidates show promise in all of these areas, 





If intravaginal vaccination of mice with these vaccine candidates has yielded 
good results, a number of further analyses using different animal models and 
inoculation routes should be used. A HSV-2 vaccine would not be widely accepted or 
used if it required intravaginal vaccination for humans considering cultural norms and 
social stigma surrounding STIs and sex, especially in areas of high HSV-2/HIV co-
infection such as sub-Saharan Africa (Rajagopal et al. 2014); inability to intravaginally 
inoculate men as they obviously do not possess vaginal mucosal areas; individual 
embarrassment and unwillingness to expose intimate areas to doctors; fear of 
harassment or retaliation, especially for young, unmarried, sexually active women; and 
fear of pain or discomfort of receiving the vaccine, more conventional vaccination 
routes such as intramuscularly (i.m.) or intradermally (i.d.) must be evaluated (Zhu et 
al. 2014). Therefore, these vaccine candidates should be tested in mice at least i.m. with 
all the above variables studied to see if it generates a comparable immune response to 
intravaginal inoculation. Then the same studies detailed above should be performed in 
guinea pigs since they do have spontaneous reactivation of HSV-2 like humans, so the 
vaccine candidate’s ability to stop reactivation can be assessed.     
Monoclonal gD and gB Antibody Analysis. Monoclonal gD and gB antibodies will be 
further assessed for neutralization activity against wild-type HSV-2 in neutralization 
assays to confidently determine their IC50s. Based on data already gathered by Bender, 
Lazear and colleagues, the antibodies I have chosen to focus on are MC2, DL11, 1D3, 
and C226 because of their low ID50 for HSV-2 (Bender et al. 2007; Lazear et al. 2012). 





colleagues should be examined in vitro by neutralization assay, especially common-
type antibodies that recognize HSV-1 and HSV-2.  
Monoclonal gD and gB Antibody Animal Studies. In an effort to determine the CoPs of 
HSV-2, BL/6 6 week old naïve female mice will be pre-treated with different doses of 
the monoclonal gD and gB antibodies listed above before being challenged with 
different doses of wild-type HSV-2 to see how well they protect the mice from infection 
and disease. Experiments elaborated for the CPBD vaccine candidates would be done 
































        
UL30 633 G A silent 8999 A : 8966 
(99.6%) 
63897 
UL31 594 C T silent 8678 A : 8641 
(99.6%) 
67256 
UL34 776 C T aa 
change 
A>V 
6599 T : 6492 
(98.4%) 
70894 
Table 1: Confirmation of R519-Specific Mutations. Before CPBD with SAVE, any mutations 
in the genome must be identified to ensure the deoptimized sequence encodes the correct amino 
acid changes. The ORFs of UL30, UL31, and UL34 of R519 were aligned to multiple HSV-2 
strains to identify mutations compared to the reference HSV-2 strain HG52. Only three 
mutations were found in these three genes: two silent mutations in UL30 and UL31 and one 
missense mutation in UL34, changing an alanine to a valine. These mutations were confirmed 
from a deep sequencing file of R519. Total Read Counts of the bases in question indicates how 
many times that base was sequenced whereas R519 Base Counts indicates how many times the 
R519 base was read in those sequences. Out of 8999 reads of the G>A mutation in UL30, 8966 
reads read an A in that position; out of 8678 reads of the C>T mutation in UL31, 8641 reads 
read a T in that position; and out of 6599 reads of the C>T mutation in UL34, 6492 reads read 
a T in that position. Therefore, these bases were read as the R519 expected mutated bases 














Name Primer Sequence 


















Table 2: galK Primers for UL30, UL31, and UL34. For the galK-DOG double selection process, primers 
need to have 50 base pairs homology to flanking areas connected to 20-mers of galK sequence. The 























mAb Literature IC50 for HSV-2 333 Experimental IC50 for HSV-2 R519 
   
MC2 (gD mAb) 0.781 μg/mL 2 μg/mL 
DL11 (gD mAb) 0.312 μg/mL 0.7 μg/mL 
1D3 (gD mAb) 6.2 μg/mL 0.9 μg/mL 
C226 (gB mAb) 1.2 μg/mL  20 μg/mL 
 
Table 3: Comparison of literature IC50s to experimental IC50s of gD and gB mAbs. The control 1:10 
IVIG had an IC50 of 9 μg/mL. The literature IC50s of MC2 and DL11 are relatively close to 
experimental values with both MC2 and DL11 being found as between 2-2.5-fold less effective 
compared to literature IC50s reported by Lazear et al. 2012. The experimental IC50 for 1D3 was a little 
less than 7-fold more effective than its literature IC50 reported by Lazear et al. 2012 whereas the 
experimental IC50 for C226 was about 17-fold less effective than its literature IC50 reported by Bender 
et al. 2007. This experiment was only performed once, so discrepancies between literature and 





Figure 1: HSV-2 Virion Structure. The viral DNA genome is contained in the nucleocapsid, 
which is surrounded by the tegument. The tegument is the area between the nucleocapsid and 
envelope that contains various viral proteins important for immune evasion. The envelope is 
studded with multiple glycoproteins such as gD, which mediates attachment; gB, which 
mediates fusion; and gH/gL, which activates gB. The entire envelope surface is covered with 
glycoproteins; only a few glycoproteins are shown on this diagram so as not to affect labeling 











Figure 2: HSV-2 Lifecycle. HSV-2 has a complex lifecycle that includes two tropisms. During 
primary infection, HSV-2 infects epithelial cells of the genital mucosa though binding of gD 
to herpesvirus entry mediator (HVEM), which is expressed on both epithelial and neuronal 
cells. HSV-2 undergoes lytic replication in the epithelia to cause the characteristic lesions of 
symptomatic genital herpes. The virus then infects innervating nerves in the area through 
binding of gD to nectin-1. Once HSV-2 has successfully infected the nerves, virions travel up 
the axons to the nuclei where they establish latency in the DRG. Not much information is 
known about the latent state except that the viral genome is not actively replicating, but latency-
associated transcripts (LATs) are made. Latent HSV-2 cannot be detected by the immune 
system as no epitopes are being presented, providing quite a big barrier to a cure as well as a 
vaccine. Triggers such as stress or UV light reactivate the virus from latency. Virions are 
synthesized in the nerves, travel back down the axons, and lytically infect the epithelia to create 

















Figure 3: galK Plasmid Map. pGalK is a 4176 bp plasmid in the pBlue Sk- backbone, which 
contains two oris and an AmpR gene under the AmpR promoter as a selectable marker. galK is 
under the Em7 promoter, a synthetic promoter derived from the T7 bacteriophage promoter. 
The galK ORF was isolated using HindIII and BamHI restriction endonucleases. This plasmid 











Figure 4: galK-DOG Double Selection BAC Recombineering Procedure. Primers with 50 bp 
homology to the flanking areas of the site of interest are used to amplify the galK gene from 
pGalK by PCR. SW102 cells containing H312-1B-S1 are made competent and transformed 
with the galK cassette. The galK cassette replaces the wild-type UL30, UL31, or UL34, giving 
the transformant cells the ability to grow on minimal media containing galactose. After colony 
purification, these transformants are transformed again with the CPB UL30, UL31, and UL34. 
These transformants are plated on M63 minimal media with DOG as all galK-BAC-containing 
cells will die because galK will phosphorylate DOG to a toxic intermediate. After colony 
purification, these BACs will be purified and nucleofected into Vero cells to rescue the 


























 A               B. 
Figure 5: galK PCR Products. (A.) The galK gene in pGalK was amplified by two PCR 
experiments denoted galK #1 and galK #2 using the primers shown in Table 1. This PCR 
created the galK cassette needed for the first step of the galK-DOG double selection protocol 
by attaching homology arms for UL30, UL31, or UL34 to the galK gene. Bands are about 1.3 
kb, which is the expected length of the product. Lane 1: 1 kb ladder with 1 kb band marked 
with ►; Lane 2: galK #1-UL30 PCR product; Lane 3: galK #1-UL31 PCR product; Lane 4: 
galK #1-UL34 PCR product; Lane 5: galK #2-UL30 PCR product; Lane 6: galK #2-UL31 PCR 
product; Lane 7: galK #2-UL34 PCR product (B.) The galK #1 PCR products were cleaned 
with DpnI, which degrades methylated DNA, and run on a gel. These bands were gel purified 
and rerun to estimate concentration. Bands are still at 1.3 kb as expected, but have crisper 
borders. Lane 1: 1 kb ladder; Lane 2: galK #1-UL30 DpnI-cleaned PCR product; Lane 3: galK 












Figure 6: Neutralization Assay of gD and gB mAbs. Different dilutions of gD and gB mAbs 
were incubated with HSV-2 R519 and plated on Vero cells to determine plaque count. All gD 
mAbs had IC50 values lower than that of 1:10 IVIG, indicating that they were more effective at 
neutralizing HSV-2 than 1:10 IVIG. The gB mAb C226 had a higher IC50 value than 1:10 IVIG, 
meaning that it was less effective at neutralizing HSV-2, which opposes its literature IC50 value 
reported by Bender et al. 2007. This experiment was only performed once, which may explain 
the discrepancies between the literature IC50s reported by Lazear et al. 2012 and Bender et al. 
2007 and the experimental IC50s reported here. For exact IC50 values, please see Table 3.    
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